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Abstract  
Foetal growth and development is closely related to the placental transport function, 
since any defect in this function is associated with pathological foetal growth. 
Trophoblast differentiation into a multinucleate syncytium is a key biological 
mechanism. Transcriptional regulation of fusogenic genes to promote fusion and 
capacity for placental hormonogenesis is achieved by a coordinated action of signals 
such as cAMP and MAPKs. The mammalian target of rapamycin (mTOR) acts as a 
placental growth signalling sensor, and this has been implicated in the 
pathophysiology of diseases such as intrauterine growth restriction (IUGR). This is 
also implicated in the pathological mechanism of diabetes mellitus, a disease which is 
associated with excess nutrient availability and insulin resistance. Many researchers 
have reported a relationship between changes in placental amino acid transporter 
activity and altered foetal growth. The signalling pathway of the protein kinase mTOR 
has been proposed to regulate cellular growth in response to growth factors, nutrient 
and amino acids by inducing transcription and translation. The role of mTOR 
signalling pathway in early development is confirmed by post implantation lethality 
in mouse following a complete deletion of mTOR gene. mTOR is an evolutionarily 
conserved member of the phosphatidylinositol-3-OH (PI-3)-kinase-related kinase 
(PIKKs), and its upstream activators PI3K and Akt appear to be involved in the control 
of trophoblast fusion. The precise role of mTOR in the trophoblast differentiation 
mechanisms is not well understood. 
Previous studies have shown that, fusion processes in BeWo cells is stimulated by 
inhibition of intracellular calcium and down regulation of phosphatidylinositol 3 
kinase (PI3K)/Akt pathway. Since PI3K/Akt pathway is the upstream signalling of 
mTOR pathway, we conducted this study to investigate the role of mTOR signalling 
pathway in BeWo cells differentiation. Our in-vitro studies showed that inhibition of 
mTOR by rapamycin, reduced forskolin-induced hCG release, whereas syncytin-1 and 
-2 mRNA expression was substantially augmented. These findings led us to 
investigate the effect of forskolin-driven adenylyl cyclase activation on mTOR 
expression and activity. Forskolin treatment for 24h significantly reduced mTOR 
protein expression. Moreover, within 10min of forskolin treatment, there was a 
substantial reduction in basal mTOR phosphorylation at Ser2481 and Ser2448, which 
is required for mTOR activity. This was associated with increased phosphorylation of 
p70S6K, at Ser371.Immunohistochemistry showed increased mTOR expression and 
phospho-mTOR (Ser2448/2481) staining in GDM placenta compared to controls. 
Our results identify distinct actions of mTOR on the biochemical and morphological 
differentiation of BeWo trophoblasts. In addition, it showed increased expression and 
activity of mTOR in gestational diabetes mellitus (GDM). 
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Chapter One  
Introduction 
 
 
 
1 
 
1.1. The placenta 
The placenta is the main organ that maintains fetal development and lead to a 
successful pregnancy. Its main function is to provide an immunological barrier that 
separates foetal from maternal blood, to produce important hormones and cytokines 
and to transport oxygen and important nutrient between mother and fetus (Roos et al., 
2009).  
 
Figure 1.1: Structure of chorionic villus, Adapted from 
http://imueos.wordpress.com/2010/05/25/placenta-function/.  
 
The precursor cells for the inner cell mass are formed following the first cell division 
of the fertilized ovum and develop into the fetus. The outer cell layer proliferates and 
forms the trophoblastic cell mass which differentiates into villous and extravillous 
cytotrophoblast (Chen and Olson, 2005). Cytotrophoblast is a mononucleated cell 
which plays a major role in the implantation and placental development (Malassine 
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and Cronier, 2002). Cytotrophoblasts situated between the syncytiotrophoblast and the 
basement membrane and are considered as the precursor cells for the 
syncytiotrophoblast (Handwerger, 2010). Throughout pregnancy, cytotrophoblast 
cells are separated from the developing fetus through a layer of syncytiotrophoblast 
(Knöfler et al., 2001). In extra villous space, cytotrophoblasts are characterised by 
invasive behaviour and allow penetration into maternal deciduae and myometrium 
(Pijnenborg et al., 1980). Groups of cytotrophoblasts grow rapidly to form the primary 
villi which are then converted to secondary villi following the invasion by foetal 
mesenchyme. Inside the mesenchyme, capillaries are formed which convert the 
secondary villi to tertiary (Castellucci et al., 1990b). 
In the villous space, cytotrophoblasts fuse to form a syncytiotrophoblast, which forms 
continuous, uninterrupted, multinucleated cells situated in direct contact with maternal 
blood, with the function of ensuring fetal growth. In addition, it plays a major role in 
controlling feto-maternal exchange of nutrient and gases and also producing hormones 
such as oestrogen, human placental lactogen (hPL) and human chorionic gonadotropin 
(hCG) (Knöfler et al., 2001). Many studies have shown that, isolated cultured 
cytotrophoblasts in medium enriched with foetal calf serum have the ability to fuse 
forming a multinucleated syncytium which secrete hPL, hCG and steroids similar to 
hormones secreted by STB in-vivo (Kliman et al., 1986). 
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Figure 1.2: The cytotrophoblast two differentiation pathways. 
The precursor cells for the inner cell mass are formed following the first cell division 
of the fertilized ovum which develops into foetus. The other cell forms placental stem 
cells which differentiate into villous and an extravillous cytotrophoblast, villous 
cytotrophoblasts differentiate into syncytiotrophoblast, whereas the extra villous 
cytotrophoblast differentiates into endovascular trophoblast. Adapted from 
(Handwerger, 2010). 
1.1.1. Trophoblast fusion  
Cell-cell fusion is a common and highly controlled process that occurs in almost all 
organisms including yeast, myoblast, placental trophoblast and macrophage fusion 
(Chen and Olson, 2005). 
Syncytial fusion is a process in which the separating plasma membrane of two adjacent 
cells dissolute, resulting in assembly of a multinucleated structure termed as 
syncytium. This structure is derived and preserved by continued fusion of mono-
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nucleated cells (Chen and Olson, 2004). This process does not occur spontaneously, 
but rather a number of different and distinct intracellular factors are required to 
activate and control this processes (Huppertz et al., 2006). 
Like most highly differentiated cells, the syncytiotrophoblast does not possess any 
proliferative ability. Moreover, its nuclei demonstrate average rate of RNA synthesis 
and continuous fusion of cytotrophoblast with syncytiotrophoblast is essential to 
maintain this layer throughout pregnancy (Huppertz et al., 1998). Recently, a group of 
studies have demonstrated an association between disorganisation of syncytial 
trophoblast fusion and complication of pregnancy such as intrauterine growth 
restriction (IUGR) and pre-eclampsia (Huppertz and Kaufmann, 2002). In normal 
pregnancy, the endovascular trophoblast invades the uteroplacental arteries and 
modifies it into dilated and elastic vessels which is independent of maternal vasomotor 
control. In preeclampsia, both the interstitial and the endovascular invasion of 
trophoblast are reduced resulting in increased uteroplacental vascular resistance and 
hypertension (Kaufmann et al., 2003).  
1.1.1.1. Fusogenic genes  
Fusion of intracellular membranes is certainly associated with hormone secretion and 
vesicles uptakes (Huppertz et al., 2006). In human placenta, syncytiotrophoblast 
depends on syncytial fusion of cytotrophoblast cells for the contribution of new 
material. Syncytiotrophoblast necrosis and death result within days in the absence of 
constant fusion with cytotrophoblast (Castellucci et al., 1990a).  
Furthermore, various studies have shown that syncytiotrophoblast contains fewer 
uridine than cytotrophoblasts, indicating that transcription is low in 
syncytiotrophoblast, and the syncytiotrophoblast depends largely on cytotrophoblast 
5 
 
for new protein synthesis (Huppertz et al., 1999). Around 8 percent of the human 
genome has a retroviral origin (Lander et al., 2001). However, research on non-
defective endogenous retrovirus genes resulted in detection of 16 genes, two of them 
are capable of inducing cell to cell fusion and are highly expressed in human placenta 
(de Parseval et al., 2003, Mi et al., 2000). The discovery of the envelope (env) protein 
of human endogenous retrovirus (HERV-W) was the important discovery in the 
mechanism of syncytiotrophoblast fusion (Mi et al., 2000). Northern blot analysis 
demonstrated the expression of syncytin mRNA in placenta and testes (Mi et al., 
2000). In addition, researchers have identified the presence of two homologus genes 
to human syncytin 1 and 2 in mice called syncytin A and B (Dupressoir et al., 2005). 
Syncytin 1 and syncytin 2 are encoded by HERV-W and HERV-FRD genes 
respectively and play an important role in trophoblast fusion (Lee et al., 2001, Mi et 
al., 2000). It has been shown that fusion of BeWo cells and primary trophoblasts is 
inhibited following transfection with anti-syncytin 1 antiserum. Furthermore, syncytin 
1 leads to fusion of non-fusogenic COS cells, which means that this protein is able to 
induce fusion in non-fusogenic cells. In addition, by using a specific monoclonal 
antibody, various studies have demonstrated that syncytin 2 is expressed in the 
cytoplasm and membrane of villous trophoblast. And in the second trimester, the 
expression of this protein was observed in the cytotrophoblast cells at the site of 
contact with syncytiotophoblast. (Malassine et al., 2007, Oren-Suissa and 
Podbilewicz, 2007, Vargas et al., 2009). Expression of syncytin-1 is observed in 
villous and extra villous cytotrophoblast (Frendo et al., 2003, Malassine et al., 2005). 
Malassine, et al have shown for the first time the expression of syncytin 2 in villous 
cytotrophoblast (Malassine et al., 2007). 
6 
 
1.1.1.2.  Regulation of syncytin induced trophoblast fusion  
The processes of trophoblast fusion is tightly controlled; uncontrolled fusion can lead 
to the exhaustion of a regenerative pool of villous cytotrophoblast, whereas a lower 
rate of fusion results in a function defect in syncytiotrophoblast (Pötgens et al., 2004). 
In addition to syncytin, different proteins have been suggested to be involved in the 
syncytia fusion process such as Glial Cell Missing (GCM1), a transcription factor that 
regulates syncytin expression (Black et al., 2004). 
The D mammalian retrovirus (RDR, also known as ASCT2 or ATB⁰ or SLC1A5) was 
identified as the syncytin 1 receptor (Blond et al., 2000). The addition of forskolin to 
BeWo choriocarcinoma cells and the reduction of oxygen concentration have no effect 
on the mRNA expression of RDR, even though both conditions affect syncytin-1 
mRNA expression (Huppertz et al., 2006). 
The major facilitator superfamily domain containing 2A (MFSD2A) is the receptor 
for syncytin 2 and it mediates its fusogenic activities, and both of them are expressed 
in the placenta (Esnault et al., 2008). 
Recently, the relationship between the cell fusion process and PI3K/AKT signalling 
pathway (the upstream signalling of mTORC1) has been demonstrated by Vatish et al 
who have revealed that, in addition to an increased cAMP level, the fusion process is 
associated with an inhibition of PI3K/Akt pathway and a decrease in intracellular 
calcium level (Vatish et al., 2012).  
One of the regulators of syncytin 1 expression is glial cell missing-1 (GCM1), which 
is a placental transcription factor that controls mRNA expression through two GCM1 
binding sites (Yu et al., 2002). GCM was first isolated from Drosophila melanogaster 
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and two isoforms (GCM1 and GCM2) have been identified in humans and rodents 
(Kim et al., 1998). 
The expression of GCM1 gene in mammals is tissue specific and is  limited to thymus, 
placenta and kidney (Hashemolhosseini et al., 2002). The importance of this protein 
in placental development was confirmed by KO studies in mice that showed 
embryonic lethality due to a defect in syncytiotrophoblast development following 
deletion of GCM1 protein (Schreiber et al., 2000). Researchers have also demonstrated 
that in both BeWo cells and primary trophoblast cells, cAMP or cAMP-driven protein 
kinase A (PKA) pathway induces syncytin 1/2 and GCM1 expression (Knerr et al., 
2005). 
1.1.2. Human chorionic gonadotropin (hCG) 
Human chorionic gonadotropin is a placental glycoprotein hormone which is 
necessary for human reproduction and fetal viability. It is a heterodimeric hormone 
which consists of β-subunit with 145 amino acids and α-subunit with 92 amino acids 
connected with disulphide bounds at cys110 and cys26 of β and α-subunits 
respectively (Lapthorn et al., 1994). The family of glycoprotein hormones also include 
follicle stimulating hormone (FSH), leutinizing hormone (LH) and thyroid stimulating 
hormone (TSH). The α-subunit is common to all glycoprotein hormones, while β-
subunit is unique and gives each hormone its specific biological and immunological 
function (Pierce and Parsons, 1981). 
The α-subunit of hCG hormone is encoded by a gene located on chromosome 6 (Fiddes 
et al., 1979) whereas β subunit is encoded by six genes located on chromosome 19 
(Policastro et al., 1986). Measurement of hCG is used as a marker to monitor the 
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progress of successful pregnancy, ectopic pregnancy, Down syndrome and some hCG 
secreting tumour (Xing et al., 2001).  
The β-subunit of hCG is used as a marker of pregnancy since it is the first hormone 
released by trophoblast after implantation. Its proposed functions include the 
stimulation of continuous secretion of steroid hormones by corpus luteum, modulation 
of implantation and regulation of immunological adaptation during pregnancy (Rull 
and Laan, 2005). 
Shi et al have shown that hCG plays a role in trophoblast differentiation from 
cytotrophoblast to multinucleated syncytiotrophoblast which produces a large amount 
of hCG compared with cytotrophoblast (Shi et al., 1993). In theca-interstitial cells, 
LH/hCG stimulates mTORC1 signalling pathway through phosphatidylinositol-3-
kinase/Akt pathway for the regulation of androgen biosynthesis (Palaniappan and 
Menon, 2010). 
1.1.3. Signalling molecules in the placenta  
1.1.3.1. Cyclic adenosine monophosphate (cAMP) 
Cyclic AMP is involved, as a second messenger, in intracellular signalling in response 
to various hormones, neurotransmitters and growth factors. It plays a key role in many 
cellular processes such as cell fusion and gene transcription (Tasken and Aandahl, 
2004). cAMP level is regulated by the enzyme adenylyl cyclase that controls cAMP 
synthesis and the enzyme cAMP phosphodiesterases4 (PDE4) which controls cAMP 
degradation (Houslay, 2010). cAMP activation includes binding of an extracellular 
protein to a G protein-coupled receptors (GPCR) which in turn activates the enzyme 
adenylyl cyclase resulting in the generation of cAMP. (Keryer et al., 1998). Once it is 
generated, it interacts with various cell proteins including cAMP dependent protein 
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kinas A (PKA), which regulates most of cAMP effects and consists of two classes 
known as type I and type II PKA (Tasken and Aandahl, 2004). PKA consists of two 
catalytic subunits (C) and one regulatory subunit (R), on each R subunit cAMP binds 
to two sites called A and B regulatory subunits. Three catalytic subunits (Cα, Cβ, and 
Cγ) and four regulatory subunits (RIα, RIβ, RIIα, and RIIβ) have been identified. RIα 
and RIIα are expressed in all cell types, whereas RIβ and RIIβ are tissue specific. 
Furthermore, RI isoform is localized mainly in the cytosol, whereas RII isoform is 
targeted to structures such as nuclear membranes, cytoskeleton and cytoplasmic 
organelles such as Golgi apparatus. Extracts from human placenta showed the 
expression of both PKA type I and type II (Keryer et al., 1998). 
cAMP plays a key role in BeWo choriocarcinoma cells and primary trophoblast 
differentiation. Studies have shown that cAMP/PKA signaling pathway stimulates the 
expression of both syncytin and GCM1 in BeWo cells and primary trophoblast (Knerr 
et al., 2005). In addition, it has been shown that in BeWo cells ERK 1/2 and p38MAPK 
are the downstream effectors of adenylyl cyclase, and they play a key role in hCG 
secretion and fusogenic gene expression (Delidaki et al., 2011). 
1.1.3.2. Mammalian target of rapamycin (mTOR)-The placental 
nutrient sensor  
During the last decade mTOR, (also called FRAP, RAFT, RAPT, or SEP) 
(Wullschleger et al., 2006) has appeared as the main regulator of cell growth and 
metabolism. Abnormalities in mTOR signalling pathway have been linked to aging 
and to human diseases such as type 2 diabetes, cancer and obesity, which may indicate 
that targeting  mTOR function could help treating many human diseases (Laplante and 
Sabatini, 2012). 
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mTOR is one of the phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) 
family (PIKKs), together with ATM, ATR, DNA-PK, and hSMG1. They all have C-
terminal protein kinase domains which are similar to the lipid kinase PI3K, hence 
giving the family its name. It is a huge protein (289kD) (Ballou and Lin, 2008) and is 
considered as an atypical serine/threonine protein kinase which incorporates various 
upstream signals to control growth-related processes involving mRNA translation, 
ribosomal biogenesis, autophagy and cellular metabolism (Laplante and Sabatini, 
2012). While P1KKs family respond to geno-toxic stress, mTOR responds to stress 
related to nutrient and energy.  
Furthermore, unlike PIKK family, in addition to its kinase domain, mTOR has many 
heat repeat in its N-terminal end as well as FAT domain of vague function (Sengupta 
et al., 2010). mTOR presents in two different complexes (figure 1.3), mTOR complex 
1 (mTORC1) and mTOR complex 2 (mTORC2), mTORC1 consists mainly of mTOR, 
mammalian lethal with sec-13 protein 8 (mLST8) also known as GBL, DEP domain 
contains mTOR interacting protein (DEPTOR), raptor (regulatory associated protein 
of mTOR) and is considered to be rapamycin sensitive (Hara et al., 2002). 
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Figure 1.3: Protein component of mTORC1 and mTORC2 
The core protein of mTORC1 are mTOR, raptor, and mLST8. In addition, it also binds 
to non-conserved proteins, which include PRAS40, DEPTOR, and Rheb-GTP. 
mTORC2 consists of core proteins mTOR, rictor, and mLST8, in addition to mSin1, 
DEPTOR, and PROTOR/PPR5. The mTORC2 regulates cell structure and survival by 
signaling to SGK and Akt. Adapted from (Frost and Lang, 2011).  
Two members of this protein complex GBL and raptor, the two mTOR interacting 
proteins, are essential for the phosphorylation of S6K1 and 4E-BP1 (the downstream 
effectors of mTORC1) both in vivo and in vitro (Kim et al., 2002). 
Expression of the phosphorylated forms of P70S6K and the inhibition of the 4EBP1 
are used as a measure of the activity of mTORC1 (Roos et al., 2007).  
mTORC2, in addition to mTOR and GBL, contains the rapamycin insensitive 
component of mTOR (rictor) and mammalian stress-activated map kinase-interacting 
protein 1 (mSin1) (Laplante and Sabatini, 2012). 
Compared to mTORC1, mLST8 is important for mTORC2 activation both in-vivo and 
in-vitro (Guertin et al., 2006). Similar to mTORC1, mTORC2 is inhibited when 
Deptor binds to the FAT domain of mTOR (Peterson et al., 2009). 
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mTORC2, by phosphorylating and activating the Akt (Ser473)/PKB, plays a role in 
controlling cell proliferation and survival (Sarbassov et al., 2005). Even though 
mTORC2 is said to be rapamycin insensitive, it has been mentioned that prolonged 
exposure to rapamycin leads to sequestration of mTORC1 which reduces the 
accessibility of the mTOR for the mTORC2 assembly (Sarbassov et al., 2006). 
1.1.3.2.1 Domain structure of mTOR 
The 2459 amino acid protein of mTOR consists of highly preserved domains (Kim et 
al., 2002), specifically the heat repeat sequence located in the NH2-terminal part of 
mTOR (Perry and Kleckner, 2003), the kinase domain located in the COOH-terminal, 
and it is similar to the catalytic domain of the PI3K (figure 1.4). Between the NH2-
terminal and the kinase domain situated the FRB domain, which is the binding site for 
rapamycin-FKBP12 complex (Sekulic et al., 2000). 
PRAS40 has been categorized as a negative regulator of mTORC1(Wang et al., 2007). 
The role of the other mTOR binding protein is still uncertain (Yip et al., 2010). Earlier 
studies showed that raptor may play a role in controlling mTORC1 assembly and 
mediating mTORC1 activity and subcellular localization (Hara et al., 2002). 
It has been shown that the FATC domain is a very important for mTOR activity and 
the removal of even one amino acid from this domain inhibits mTOR activity 
(Peterson et al., 2000). Furthermore, some studies have suggested that both FATC and 
FAT domains act together to expose the catalytic domain of mTORC1 (Sekulic et al., 
2000). Raptor is also important for mTORC1 activity since Raptor-free mTORC1 fails 
to phosphorylate 4E-BP1, but it is still able to phosphorylate S6K1 (Yip et al., 2010). 
However, prolonged loss of mLST8 has no impact on mTORC1 activity although it 
affects the assembly and action of mTORC2 (Guertin et al., 2006).  
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Figure 1.4: Domain structure of mTOR Adapted from (Bové et al., 2011).  
 
1.1.3.2.2 Downstream effectors of mTORC1 
mTORC1 plays a major role in controlling growth in response to upstream inputs 
(Sengupta et al., 2010). The activation of mTOR is initiated when Akt is 
phosphorylated through PI3K dependent or independent pathway leading to 
downstream activation of various cellular pathways. Akt inhibits the tuberous sclerosis 
complex 1 and 2 (Tsc1 & Tsc2) which are known inhibitors to mTOR. The activated 
Akt also leads to phosphorylation of mTOR at Ser2448, and subsequent 
phosphorylation (activation) of P70S6K at Thr389 and phosphorylation (inhibition) of 
eukaryotic initiation 4E binding protein-1 (4EBP-1). The later phosphorylation is 
required for completely activation of this pathway, since when it is bound to elf, it 
inhibits further protein synthesis (Hay and Sonenberg, 2004). 
One of the main substrates of mTOR is the 40s ribosomal protein s6 kinas. S6K1, the 
main isoform of the S6k, regulates cell growth proliferation and differentiation by 
playing a major role in ribosome biogenesis, cell cycle progression and protein 
synthesis (Duvel et al., 2010). 
P70s6k has been identified as the kinase that controls the processes of phosphorylation 
of 40S ribosomal protein S6. Inhibition of p70s6k activation in-vivo by the 
14 
 
immunosuppressant rapamycin will interfere with the ability of the cell progression 
through G1 phase of the cell cycle (Ferrari et al., 1993). Since it plays a role in cell 
growth and insulin sensitivity, abnormal activity of S6K1 has a major role in the 
progression of tumours, diabetes mellitus, obesity and aging (Dann et al., 2007). 
mTORC1 phosphorylate S6K1 at Thr389 (Fingar and Blenis, 2004). For P70s6k Ser 
371, it has been mentioned that, Ser371 is crucial for Thr389 phosphorylation and in 
turn S6K1 activity. However, it is still vague how Ser371 is phosphorylated (Dann et 
al., 2007). 
Protein synthesis 
Cell growth requires a high energy level in order to keep protein synthesis at a high 
rate. Since this process is started when adequate levels of nutrient (amino acid and 
energy) and growth factor are available, mTOR is believed to control protein 
translation by integrating environmental signals from amino acids and growth factors 
(Sengupta et al., 2010). 
mTORC1 regulates the entire translational processes and also the translation of 
messenger RNA (mRNAs) to stimulate cell growth and proliferation. In vitro studies 
have shown that mTOR controls protein synthesis partly by phosphorylating the 
downstream signalling p70s6k and eukaryotic initiation factor 4E (elF-4E) binding 
protein 1 (4E-BP1). These two compounds subsequently facilitate translation and 
protein synthesis (Ma and Blenis, 2009). When dephosphorylated, the 4E-BPs inhibits 
mRNA translation (Pause et al., 1994), this inhibitory effect is blocked when 
mTORC1 induces 4E-BP1 phosphorylation (Dowling et al., 2010). 
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Regulation of autophagy 
Autophagy is a physiological process in which cells degrade cytoplasmic proteins and 
organelles inside lysosomes (Klionsky, 2007). Production of energy and protein 
synthesis can be maintained through autophagy since the degradation of protein 
complexes and cellular organelles provide the anabolic processes with biological 
material (Laplante and Sabatini, 2009). 
mTORC1 is the key regulator of autophagy; when growth factors and nutrients are 
available, mTORC1 inhibits autophagy initiation (Noda and Ohsumi, 1998). 
Autophagy promoting states include starvation, growth factor deficiency, infection 
and oxidative stress. mTORC1 is also reactivated when amino acids are released from 
the degraded proteins, and the activated mTORC1 will eventually restore the 
intracellular lysosome population (Yu et al., 2010). 
This process is required for cellular adaptation during starvation and for the recycling 
of dead organelles. Inhibition of mTORC1 leads to the formation of autophagosomes 
which results in the degradation of the cellular components (Laplante and Sabatini, 
2012). Autophagy is strongly stimulated by the inhibition of mTORC1 (Martina et al., 
2012). 
mTORC1 regulates autophagy via a group of protein complexes which consists of un-
51-like kinase 1 (ULK1) that is the key protein in autophagy initiation. Focal adhesion 
kinase family-interacting protein of 200kD (FIP200), and autophagy-related gene 13 
(ATG13) (Laplante and Sabatini, 2009). ULK1, ATG13 and FIP200 form a complex 
which activates ULK1 (Ganley et al., 2009). In rich nutrient conditions, mTORC1 
binds to the Ulk1-Atg13-FIP200 complex, by direct binding of Raptor to Ulk1/2, 
mTOR then phosphorylates ATG13 leads to down regulation of ULK1 kinase, thereby 
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inhibiting autophagy. In addition, AMPK indirectly leads to the induction of 
autophagy by inhibiting mTORC1 through phosphorylation of Raptor or TSC2 
(Ravikumar et al., 2010).  
                                         
Figure 1.5: m TORC1 and autophagy regulation  
Ulk1 form complex with Atg13, and FIP200. Under rich growth conditions, mTORC1 
phosphorylates Ulk1 and Atg13, thus inhibiting the Ulk1/2 kinase activity. In 
starvation, Ulk1/2 are rapidly dephosphorylated, and Ulk1/2 phosphorylates Atg13 
and FIP200 converting the complex to the pre-autophagosomal membrane and 
autophagy initiation. Adapted from (Ravikumar et al., 2010).  
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Nutrient transport  
Some researchers have suggested that amino acids transporters are among the down 
streams of mTORC1 (Edinger, 2007). Some supporting studies reported the inhibition 
of mRNA expression of some amino acid transporters when BJAB (EBV-negative 
Burkitt’s lymphoma) cell line was treated with rapamycin (Peng et al., 2002). 
Furthermore, it was reported that in Drosophila, the surface expression of cationic 
amino acid transporters is stimulated by mTOR (Hennig et al., 2006). 
In L6 myotubes, rapamycin inhibits the up-regulation of system A amino acid 
transporter activity by leucin (Peyrollier et al., 2000). Amino acids are transported 
across the plasma membranes by transporter proteins, the activity of three of them has 
been shown to be altered when foetal growth is changed (Roos et al., 2009). 
The activity of System A transporter (transports small neutral amino acids such as 
alanine, glutamine and serine) has been found to be increased in microvillous plasma 
membrane (MVM) isolated from pregnancy complicated with fetal overgrowth. 
However, the activity of this system was shown to be down regulated in IUGR. The 
other amino acids transport system is system L which transports big amino acids such 
as leucine was found to be down regulated in MVM and basement plasma membrane 
of pregnancy with IUGR (Jansson et al., 2002, Mahendran et al., 1993). 
18 
 
 
Figure 1.6: A model of mTOR signalling pathway regulating nutrient transport across placenta 
adapted from (Roos et al., 2009). 
 
Lipogenesis  
Many studies suggested that mTORC1 plays a role in adipogenesis since the inhibition 
of mTORC1 with rapamycin leads to impairment of adipogenesis. In contrast, up 
regulation of mTORC1 signalling, by silencing TSC1/2 expression through siRNA 
(small interfering RNA), induces adipogenesis. The downstream signal transducer of 
mTORC1, 4E-BP1 is thought to mediate this effect by regulating the translation of 
peroxisome proliferator-activated receptor (PPARg) (Lamming and Sabatini, 2013). 
In rat hepatocyte, mTORC1 has been shown to be involved in regulating the 
transcription factor Sterol Regulatory Element Binding Protein (SREBP) which is 
involved in activation of lipogenic enzymes (Owen et al., 2012). 
Another evidence for the role of mTORC1 in lipogenesis is the failure of mice with 
S6K1gene knockdown to gain weight because of defective adipocytes generation 
(Carnevalli et al., 2010). 
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Negative feedback regulator of IRS1 by S6K1 
The presence of negative feedback loop from mTORC1-S6K1 signalling pathway to 
the IRS-PI3K-PDK1-Akt pathway has been shown by various studies (Harrington et 
al., 2004, Um et al., 2004). S6K1 directly phosphorylate and inactivate IRS1 function 
leading to uncoupling of IRS-1 from PI3K resulting in PI3K inhibition (Um et al., 
2004). It has been postulated that the inhibition of insulin-PI3K signalling is related to 
metabolic disorder such as obesity and diabetes. Aberrant activation of mTOR 
signalling pathway because of TSC deficiency or increased nutrient might lead to the 
inhibition of PI3K pathway and contribution in development of insulin resistance and 
type 2 diabetes (Wullschleger et al., 2006). 
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1.1.3.2.3 The upstream effectors of mTOR  
 
Figure 1.7: mTOR signalling pathway  
Activation of PI3K by growth factor resulted in increased production of PI3, 4, 5-
triphosphate. Akt then binds to PI (3, 4, 5). P3 leads to phosphorylation and activation 
of Thr308 by PDK1and Ser 473 by mTORC2. The complex, TSC1/TSC2, inhibits m 
TORC1 by converting the GTPase activity of Rheb to inactive GDP-bound form.TSC1 
/TSC2 complex can be phosphorylated and inhibited by Akt which maintains the Rheb 
in the active GTP-bound form. AMPK activates TSC1/TSC2 complex which in turn 
inhibits mTORC1, as in low energy conditions. adapted from (Ballou and Lin, 2008). 
 
Growth factor 
Growth factors control mTOR signalling pathway through PI3/Akt pathway. Insulin 
or insulin like growth factor (IGF) binding to their corresponding receptors leads to 
phosphorylation of insulin receptor substrate (IRS-1) and PI3K recruitment. The 
association of PI3K to IRS-1 phosphorylate phosphatidylinositol-4,5-phosphate 
(PIP2) to phosphatidylinositol-3,4,5-phosphate (PIP3) (Wullschleger et al., 2006)). 
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Akt controls mTORC1 via tuberous sclerosis complex (TSC). TSC1 & 2 form a 
complex that can convert Rheb to its inactive GDP-bound and consequently 
suppresses mTORC1 activity. However, IGF-1 activates Akt which in turn 
phosphorylates TSC2 at Ser939 which will maintain  Rheb in its GTP-bound forms to 
stimulates mTORC1 down signalling to S6K and 4EBP1 (Ballou and Lin, 2008). 
A main advance in the understanding of regulation of mTOR signalling by growth 
factor and Akt was through the discovery of TSC1 and TSC2 proteins (also known as 
hamartin and tuberin respectively) as the upstream regulators of mTORC1. TSC1 and 
TSC2 are encoded by tuberous sclerosis complex 1 (TSC1) and tuberous sclerosis 
complex 2 (TSC2) genes (Cheadle et al., 2000). In Drosophila, mutation in TSC1 or 
TSC2 leads to increased cell and organ size (Hay and Sonenberg, 2004). 
Nutrient  
Amino acid has been suggested to stimulate mTORC1 activity by inhibiting TSC1/2, 
or through activation of Rheb, (Gao et al., 2002). Amino acids limited availability, 
especially the unavailability of leucine, leads to inactivation of S6K1 and 4E-BP1. In 
contrast, in a condition where leucine availability is restored phosphorylation and 
activation of S6K1 and 4E-BP1 are retained in an mTORC1 dependent way (Hay and 
Sonenberg, 2004). Previous studies have shown that silencing TSC1/TSC2 expression 
leads to amino acids deprivation resistance, which indicates that TSC1/TSC2 might 
play a role in mTOR regulation by amino acids (Gao et al., 2002). 
Energy and Oxygen level  
mTORC1 is affected by the energy condition of a cell through AMP-activated protein 
kinase (AMPK). Low energy, high adenosine monophosphate/adenosine triphosphate 
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(AMP/ATP) ratio and low oxygen level lead to activation of AMPK, which is 
considered to be one of the major mTOR controlling substances and an intracellular 
energy-sensor which is stimulated by even minimal change in ATP level (Kahn et al., 
2005). The upstream kinas for AMPK is suggested to be the tumour suppressor LKB1 
which in conjunction with AMP responds to energy deprivation by activating AMPK, 
which consequently activates TSC2 leading to down regulation of mTORC1 signalling 
(Wullschleger et al., 2006). 
An increase in AMP/ATP ratio activates TSC1 and converts Rheb to its GDP form 
resulting in inhibition of mTORC1. When activated, AMPK inhibits energy requiring 
processes such as protein synthesis and up regulates ATP-producing processes like 
fatty acid oxidation (Inoki et al., 2003). 
The effect of AMPK mediated pathway on mTOR activity can be demonstrated by 
measuring S6K1 phosphorylation (Kimura et al., 2003). In agreement, cell exposure 
to 5-aminoamidazole 4-carboxyamide (AICAR, an AMP analog), inhibits S6K1 and 
4E-BP1 phosphorylation, leading to the inhibition of mTORC1 signalling (Inoki et al., 
2003). A study by Kinura et al has shown that the mTOR and AMPK signalling 
pathways are linked, the evidence for this is that, AICAR inhibits p70s6k 
phosphorylation in a time dependent manner, second the reagents that activate AMPK 
inhibit p70s6k in various cell lines including HEK293 cells line, third rapamycin-
resistant p70s6k is also resistant to AICAR (Kimura et al., 2003).  
In addition, researchers have shown that mTORC1 might act as a sensor to the hypoxic 
status of the cell via two homologues proteins; the expression of transcriptional 
regulation of DNA damage protein response 1 and 2 (REDD1 and REDD2) 
(Brugarolas et al., 2004). REED is the downstream effector of AKT and the upstream 
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of TSC1/2. Hypoxia up regulates REDD1 that stimulates TSC2 and subsequently 
inhibits mTORC1. REDD also inhibits mTORC1 through LKB1/AMPK signalling 
pathway. Furthermore, prolonged hypoxia resulted in increased AMP/ATP ratio and 
activation of AMPK signalling (Wullschleger et al., 2006). 
1.1.3.2.4 mTORC2 
mTORC2 was believed to be rapamycin insensitive since acute treatment with 
rapamycin does not affect mTORC2. Rapamycin-FKBP12 complex (this complex 
binds to and inhibits mTORC1) does not bind to mTORC2, since mTORC2 lack 
Raptor (Sarbassov et al., 2004). mTORC2, unlike mTORC1, does not respond to 
nutrient but it does respond to insulin through PI3K dependent mechanism (Laplante 
and Sabatini, 2012). In addition to its activation by PI3K-P1P3, AKT is also activated 
by mTORC2 by phosphorylation at the hydrophobic site (Ser473), while the kinase 
that phosphorylates Akt at Thr308 is PDK1 (Sarbassov et al., 2005). mTORC2 plays 
major roles in proliferation, metabolism and cell survival. Those processes are highly 
dependent on Akt activation, mTORC2 phosphorylates (and consequently activates) 
Akt at Ser473 which stimulates these processes through various effectors such as the 
transcription factors forkhead box protein O1 (FoxO1) and FoxO3a, the later control 
gene expression implicated in cellular metabolism, stress resistance, apoptosis and cell 
cycle arrest. Cytoskeleton organization is also controlled by mTORC2. Some studies 
have shown that mTORC2 knock down negatively affects actin polymerization and 
they proposed that mTORC2 regulates actin cytoskeleton by phosphorylating and 
activating protein kinase Cα; however, the mechanism by which mTORC2 controls 
this has not been identified (Laplante and Sabatini, 2009). 
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1.1.3.2.5 Rapamycin 
Rapamycin is a macrocyclic antibiotic generated by the bacterium streptomyces 
hygroscopicus, a streptomycete that was found in a soil sample from Rapa Nui Island 
in the early 1970s (Sehgal, 1998). Initially, it was used for its antifungal activity, but 
it was also discovered to have a potent immunosuppressive effect (which was 
considered to be undesirable side effect) since it inhibits the proliferation of B and T 
cells. It also inhibits mammalian cell proliferation and has anti-tumour activity 
(Sehgal, 2003). The PI3K/Akt/mTOR pathway controls cell growth and metabolism, 
a function that is affected by rapamycin and other mTOR kinas inhibitors (Xue et al., 
2009). 
Mechanism of action of rapamycin 
The discovery of mTOR came as a result of studies investigating the intracellular 
target of the rapamycin-FKBP complex (Brown et al., 1994). Early studies have 
reported that binding rapamycin-FKBP complex to mTORC1 results in structural 
changes that weaken mTOR-raptor assembly (Kim et al., 2002). Rapamycin belongs 
to a group of macro-cyclic immunosuppressive agents that bind to a specific cytosolic 
binding proteins in order to produce its cellular action. Rapamycin and FK506 bind to 
the same immunophyllins known as FK506 binding proteins (FKBPs) (Sehgal, 1998).  
Even though there is no doubt that rapamycin-FKBP1 complex inhibits the kinase 
activity of mTOR to block downstream signals in-vivo (Brown et al., 1995), the 
mechanisms of inhibition of mTOR activity by rapamycin remain unclear (Fingar and 
Blenis, 2004). 
Various FKBP family have been identified, genetic studies have reported that the 
12kDa FK506 binding protein (FKBP12) is the most important binding protein with 
25 
 
which rapamycin forms a complex that interacts with and inhibits mTOR when it is 
an element of mTORC1 (since mTORC2 lack raptor), to produce its 
immunosuppressive effect (Brown et al., 1994).  
The amino acid terminal of mTOR has FKBP12-rapamycin binding domain (FRB 
domain) that is located between the kinase and FAT domains of mTORC1 (Figure 
1.4). FKBP12-rapamycin complex binds to FRB domain and exerts its inhibitory 
effect.  
 This mechanism allows the inhibition of phosphorylation/activation of 
p70S6K and translation of special mRNA encoding protein (Dumont and Su, 
1996). 
  mTORC1 auto phosphorylation is also inhibited by rapamycin/FKBP12 
complex, this complex also weakens mTOR activity through destabilizing 
mTOR-Raptor complex (Kim et al., 2002).  
 mTOR also stimulates protein translation by phosphorylating eIF-4E binding 
proteins (4E-BP1) (Brunn et al., 1997), when phosphorylated, 4E-BP1 affinity 
for eIF-4E is decreased. This leads to translation of mRNAs and consequently 
cell growth and proliferation, these activities are inhibited by rapamycin 
(Sehgal, 2003).  
However, some studies argued that rapamycin appears less effective in the treatment 
of some cancers possibly due to the loss of negative feedback effect of mTORC1/S6K 
on Akt which leads to  phosphorylation of Akt through mTORC2 at Ser473 (Laplante 
and Sabatini, 2012).  
Furthermore, upon activation by mTORC1, S6K phosphorylates insulin receptor 
substrate-1(IRS-1) which reduces the capability of GFs to activate receptor tyrosine 
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kinase and when P70S6K is inhibited by rapamycin, this negative feedback effect of 
P70S6K is lost (Harrington et al., 2004). 
Recently a model for the inhibition of mTORC1 by rapamycin has been suggested 
where the binding of FKBP12-rapamycin complex to mTORC1 leads to 
conformational alteration in mTOR which affects the interaction between mTOR and 
raptor. Furthermore, the rapamycin-FKBP12 complex blocks the binding site for 
S6K1. The binding of another complex to mTORC1 or augmented effect of the first 
complex causes a complete fragmentation of mTORC1 and elimination of 4E-BP1 
phosphorylation (Yip et al., 2010). 
1.1.4. Models for studying human placental function  
BeWo cell is a human trophoblast choriocarcinom-derived cell line, characterised by 
cytotrophoblastic properties and reserve numerous placental differentiation markers. 
They also have the ability to produce human chorionic gonadotrophin (hCG), alkaline 
phosphatase and placental lactogen (hPL) (Nickel et al., 1993). 
BeWo cells have a slow fusion rate which can be initiated by treating BeWo cells with 
forskolin (Wice et al., 1990). The incubation of these cells with forskolin resulted in 
the activation of adenylyl cyclase (AC), and an increased production of Cyclic AMP 
(cAMP). cAMP in turn induces the differentiation of cytotrophoblast to 
syncytiotrophoblast and syncytia formation, the fused cytotrophoblast then produces 
various hormones such as human chorionic gonadotropin (hCG) similar to first 
trimester trophoblasts (Orendi et al., 2010). 8-Bromoadenosine-3',5'-cyclic 
monophosphate (8-Br-cAMP) an exogenous cAMP analogue can also be used to 
induce cell differentiation (Chen et al., 2011).  
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Morphological appearance of undifferentiated BeWo cells is similar to primary 
trophoblast with nearby cells position with apical projection, (Bode et al., 2006). 
Unlike BeWo cells, JEG-3 cells do not fuse in response to cAMP analogue, but they 
have the ability to secrete hormones like hPL, estradiol, estrone, hCG and progesterone 
(CHOU, 1982, Kohler and Bridson, 1971). 
Coutifaris et al have examined E-cadherin, the Caᶧ² dependent cell adhesion molecule, 
during the differentiation of BeWo cells, JEG-3 cells and cytotrophoblast cells from 
human chorionic villi. They noticed that only JEG-3 cells were unable to form 
multinucleated syncytium (Coutifaris et al., 1991).  
In this work I have used the BeWo choriocarcinoma cell line to investigate the effect 
of mTOR on their fusigenic capacity and hCG production and this is achieved by using 
BeWo cells in their undifferentiated (forskolin untreated) and differentiated (forskolin 
treated) forms.  
1.1.5. Gestational diabetes mellitus as a disease of placenta  
Gestational diabetes mellitus (GDM) is defined as glucose intolerance of any degree 
with onset or first detection during pregnancy (Metzger, 1991), and is characterised 
by decreased glucose clearance monitored during oral glucose tolerance test (Bari et 
al., 2014).  
According to the NICE Guideline 2015 (NICE, 2015), GDM is diagnosed if the 
woman has either  
 A fasting plasma glucose level of 5.6 mmol/l or above or 
 A 2-hour plasma glucose level of 7.8 mmol/l or above. 
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It has been estimated that 2-3% of all pregnancies are complicated by diabetes, and 
the gestational diabetes represents 90% of all cases of diabetes diagnosed during 
pregnancy (Bentley-Lewis et al., 2008). In spite of development in clinical 
management of diabetes, there is still increased perinatal morbidity in pregnancy 
complicated by GDM (Jansson et al., 2002). GDM is characterised by decreased 
insulin secretion associated with insulin resistance (Vejrazkova et al., 2014). The 
nature and extent of structural and functional changes in placenta of GDM depend on 
glycaemic control and modality of treatment (Desoye and Hauguel-de Mouzon, 2007). 
1.1.5.1. Pathophysiology 
The role of insulin is to regulate the storage and release of glucose, amino acid and 
fat. Insulin stimulates the enzyme lipoprotein lipase resulted in lipolysis of 
triglycerides in blood and release of free fatty acids (FFA). Insulin stimulates the 
transport of FFAs to adipocytes which are then stored as lipids. In addition, by binding 
with insulin receptors, it stimulates glucose entrance to the cells and enhances the 
storage of some glucose as glycogen (Sonksen and Sonksen, 2000). However, 
pregnancy itself is potentially diabetogenic. Prolactin, cortisol and progesterone and 
hPL; these hormones inhibit IRS-1 phosphorylation leading to profound insulin 
resistance (Kuhl, 1998). 
GDM is connected to placental function and a number of placental hormones and 
molecules have been involved in insulin resistance in GDM (Desoye and Hauguel-de 
Mouzon, 2007). Human pregnancy is associated with a series of metabolic changes 
that result in adipose tissue growth in early pregnancy and insulin resistance with 
increased lipolysis in late gestation. Early pregnancy is also associated with increased 
insulin secretion from pancreatic β-cell, however, insulin resistance is either 
decreased, unchanged or even increased. Late pregnancy is characterized by insulin 
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resistance and increased lipolysis with increased free fatty acids formation. To 
maintain euglycemia in the mother, normal pregnancy is associated with 200% 
increase in insulin secretion and 50% decrease in glucose disposal by insulin (Barbour 
et al., 2007). 
The changes in late pregnancy involve decreased insulin receptors phosphorylation, 
reduced expression of IRS-1 and inhibited phosphoinositide 3-kinase (PI3-kinase) 
response to insulin, the purpose of these changes is to spare glucose, amino acids and 
fatty acids for the fetus (Vejrazkova et al., 2014). 
GDM characterized by decreased insulin secretion coupled with increased insulin 
resistance induced by pregnancy. At cellular level, women with GDM show signs of 
subclinical inflammation with increased TNF-α, which is shown to impair insulin 
activity by inhibiting adiponectin, (insulin-sensitizing hormone) and subsequently 
reducing insulin receptor tyrosine kinase activity. Insulin receptors are highly 
expressed by placenta relative to other tissues and their location develops and changes 
as pregnancy progresses. Early in gestation, they are located in syncytiotrophoblast 
microvillous membrane, whereas at term, they are mainly found in the endometrium 
(Desoye et al., 1994). 
Tumour necrosis factor α (TNFα) has also been shown to play a role in GDM. All 
cytokines including TNFα, leptin and resistin are expressed by placenta and 
adipocytes. Some of these cytokines play a major role in controlling insulin action 
which might indicate a possible interaction between placenta and adipose tissue in the 
pathophysiology of GDM and insulin resistance (Desoye and Hauguel-de Mouzon, 
2007). 
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In adipose tissue, the peroxisome proliferator-activated receptor γ (PPARγ) decreases 
with increased lipolysis and acceleration of IR of the adipose tissue. This will lead to 
the elevation of post prandial FFAs and an increased glucose production by the liver. 
Thus, decreased adiponectin production, effect of placental hormones, in addition to 
increased lipolysis, all these factors result in severe insulin resistance (IR) in muscle, 
adipose tissue and liver in women with GDM (Barbour et al., 2007). 
As mentioned above, many factors contribute to the development of insulin resistance 
in GDM which include changes in growth hormones and cortisol secretion which act 
as insulin antagonists, secretion of human placental lactogen which alters fatty acid 
and glucose metabolism that results in increased lipolysis and decrease glucose uptake, 
in addition to oestrogen and progesterone which affect insulin glucose balance (Ural 
and Repke, 2008). 
1.1.5.2. The Risk factors for GDM 
Various risk factors are associated with the development of GDM. According to the 
Nice guideline (NICE, 2015) the following are considered as risk factors for 
developing GDM: 
 history of macrosomia (birth weight > 4.5kg), 
  family origin of an ethnic group with a higher rate of type II diabetes (South 
Asian, black Caribbean, Middle Eastern), 
  high body mass index (above 30kg/m²), 
 and family history of diabetes (first-degree relative with diabetes).  
Other risk factors include history of unexplained stillbirth and essential hypertension 
and hypertension related to pregnancy (Xiong et al., 2001).  
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It has been shown in a meta-analysis of literature which estimated that the risk of 
developing GDM in obese and severely obese women is four and eight times 
respectively compared to normal weight pregnant women (Chu et al., 2007). 
Furthermore, it has been found that obese pregnant women are found to have elevated 
fasting insulin level with increased insulin resistance compared with lean pregnant 
women (Catalano et al., 2003).  
Maternal age older than 25years, in addition to previous history of GDM and persistent 
glucosuria, are also known risk factors for GDM. However, in 50% of GDM no risk 
factors were identified (Xiong et al., 2001, Ural and Repke, 2008). 
1.1.5.3. Consequences of GDM 
Normal pregnancy requires adequate proliferation and invasion of trophoblast 
throughout implantation and placentation. However, the changes in maternal 
environment in diabetes can affect this processes (Weiss et al., 2001). GDM is among 
the complications that interfere with normal placental and foetal development which 
may lead to increased incidence of congenital malformation and growth retardation in 
the foetus. Exposure of placenta to diabetic environment may result in functional and 
structural abnormalities including villous immaturity, increase in the surface area of 
exchange and thickening of the basement membrane, inadequate transfer of nutrient 
from mother to foetus may result in abnormal growth of the developing foetus (Desoye 
and Hauguel-de Mouzon, 2007). It has been reported by various studies that 
hyperglycaemia prevents proliferation of cell-lines of first trimester model such as 
BeWo cells, which indicates that hyperglycaemia resulted in impairment of placental 
growth in the first trimester of uncontrolled diabetic pregnancy (Weiss et al., 2001). 
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Since glucose is transferred easily across the placenta, states of maternal 
hyperglycaemia would be associated with foetal hyperglycaemia. Among those 
complications is foetal macrosomia which is characterised by an excessive amount of 
fat deposition and large shoulders. Macrosomic babies are prone to many 
complications during labour, such as shoulder dystocia. Infants of diabetic mothers 
are prone to hypoglycaemia due to excessive insulin and the cessation of transplacental 
glucose delivery from maternal blood. Furthermore, premature infants are predisposed 
to respiratory distress syndrome, in addition to the risk of developing obesity and type 
2 diabetes later in life (Coustan, 2013). Macrosomia in GDM may lead to cephalo-
pelvic disproportion which indicates caesarean section (Crowther et al., 2005). 
Epidemiological studies of GDM have shown that GDM associated with maternal 
obesity and women with GDM are at an increased risk of obstetric complication and 
future occurrence of type 2 diabetes mellitus (Feig et al., 2008).  
1.1.5.4. Screening for gestational diabetes 
In women with risk factors the test used for gestational diabetes is the 2-hour 75 g oral 
glucose tolerance test (OGTT) (NICE, 2015). Women with previous history of GDM 
should be offered early self-monitoring of blood glucose or a 2-hour 75 g OGTT after 
booking (whether in the first or second trimester), and a further 75 g 2-hour OGTT at 
24–28 weeks if the results of the first OGTT are normal. The 75g OGTT should be 
offered at 24-28 weeks for women with other risk factors for gestational diabetes 
(NICE, 2015).  
As mentioned above, gestational diabetes is diagnosed if a woman has either (NICE, 
2015) 
 a fasting plasma glucose level of 5.6 mmol/litre or above or 
 a 2-hour plasma glucose level of 7.8 mmol/litre or above. 
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1.1.6. Association between mTOR signalling pathway and placental 
pathology  
In a study conducted by Wen et al in immortalised cell line (HTR-8/SVneo), which 
originates from human trophoblast, they have shown that growth factor angiopoietin-
2 (Ang-2) and glucose stimulate trophoblast differentiation through the mTOR 
signalling pathway. The same study has demonstrated that, activation of mTOR 
pathway by Ang-2 was PI-3 kinase dependent, whereas glucose induced mTOR up 
regulation was PI-3 kinase independent. This identified mTOR as an important player 
of regulating placental trophoblast proliferation (Wen et al., 2005). In addition it has 
been suggested that invasive trophoblast differentiation is regulated by mTOR 
signalling pathway (Pollheimer and Knöfler, 2005). 
Furthermore, a study conducted by Jansson et al reported that low protein diet in 
pregnant rats is associated with decrease placental activity of insulin, leptin and mTOR 
signalling pathway as a result of maternal protein restriction, which indicates that 
maternal hormones and placental mTOR signalling might play a role in regulating 
placental amino acid transport mechanism (Jansson et al., 2006). 
mTOR is shown to be a key placental signalling pathway that regulates placental 
system A activity, and inhibition of mTOR in placenta reduces the activity of system 
L amino acid transporter (Roos et al., 2007). mTOR functions as an integrator of 
signalling molecule (such as hormones, growth factors, and nutrient) of maternal, 
foetal, and placental origin. In pregnancy complicated by IUGR, there is decreased 
activity of mTOR signalling, while in pregnancy complicated by obesity, mTOR 
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activity of placenta increased and might contribute in the high risk of delivering large 
babies (Lager and Powell, 2012).  
1.2. Thesis Hypothesis and Aims  
Vatish et al have shown that in addition to the increased cAMP, the process of BeWo 
cells fusion is associated with reduced intracellular calcium and inhibition of Type 1 
tphosphatidyinositol 3 kinase (PI3K)/Akt signalling (Vatish et al., 2012). Since 
PI3K/Akt is the up-stream signalling of mTOR and mTOR signalling pathway is 
associated with many placental pathology and intrauterine growth restriction, we 
hypothesised that mTOR regulates the function of differentiated (forskolin treated) 
BeWo cells. We aimed to characterise the role of mTOR and its downstream signalling 
in placental biology.  
To accomplish this aim, we have used the BeWo cells which have the ability to 
differentiate and are a well-established in-vitro model to study placental biological 
function (Manley et al., 2005). 
In the BeWo cell line we investigated the role of mTOR in the following: 
(a) Expression of fusogenic genes such as syncytin 1 and 2.  
(b) Endocrine capacity of cells during differentiation and syncytialization by 
monitoring secretion of human chorionic gonadotropin (hCG) which is also a 
hormonal marker of differentiation and by measuring hCG we also monitor 
biochemical differentiation.   
(c) Expression of molecules important for placental endocrine function such as 
11-βHSD2.  
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(d) The effect of BeWo cells differentiation on expression of mTOR and its related 
components.  
In placenta, we measured the expression of mTOR and its related components in 
placentae obtained from normal pregnancy compared with placenta from pregnancy 
complicated with GDM. 
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Materials and Methods 
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2.1Materials 
The listed chemicals obtained from different companies are as follows: 
2.1.1. Chemicals and Solvents 
Product Producer or Supplier 
Absolute Alcohol Hayman Ltd, Witham, UK 
Acetic acid Sigma-Aldrich 
Acrylamide Roche, Lewes, UK 
Agarose Gibco BRL, Paisley, UK 
Ammonium persulphate Sigma-Aldrich 
Bovine albumin serum (BSA) Sigma-Aldrich 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich 
Ethedium Bromide Sigma-Aldrich 
Ethanol Hayman Ltd, Witham, UK 
Isopropanol Sigma-Aldrich 
Methanol Hayman Ltd, Witham, UK 
TRITON X-X100 Sigma-Aldrich 
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2.1.2. Enzymes 
The product Producer or supplier 
dNTP(deoxynucleotide triphosphates) Bioline 
DNase 1 (RNase free) Qiagen  
Random hexamers Promega 
Reverse transcriptase Fermentas/Promega  
RNase Inhibitor Fermentas/Promeg 
Taq DN Polymerase Fermentas/Promega  
Trypsin (0.25%) Sigma-Aldrich  
5x buffer Fermentas/Promega 
2.1.3. General buffers and solution  
 DNA loading buffer 
1m Tris-HCL pH 7.5 40% glycerol (v/v), 0.1% bromphenol blue (w/v). 
 Dulbecco’s Phosphate buffered saline (PBS)  
0.132gCaCl₂ x 2H₂O, 0.2gKCl, KH₂PO₄, 0.1gMCl₂ x 6H₂O, 8.0gNaCl, 1.15g 
Na₂PO4, up to 1000ml in distilled water. 
 Pen/Strep 
100u/ml penicillin and 100 µg/ml streptomycin in PBS. 
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 Protease Inhibitor Cocktail 
1.6mg/ml benzamidine HCL, 1mg/ml phenanthroline, 1mg/ml aprotinin, 1mg/ml 
pepststin A, 1mg/ml leupeptin in absolute ethanol. 
 RIPA buffer (Santa Cruz # sc-24948) 
50mM Tris-HCL (pH 7.4), 150nM NaCl, 1mM PMSF, 1mM EDTA, 5µg/ml aprotinin, 
5µg/ml leucopeptin, 1% Triton X-100, 1% sodium deoxycholate, 0.1%SDS. 
 Trypsin EDTA in HBSS without Ca² and mg² (Trypsin-EDTA) 
0.4gKCl, 0.06g H₂PO₄, 8g NaCl, 0.35g NaHCO3, 0.048gNa₂HPO₄, 1g D-glucose, 
10ml phenol red 0.1%, 2.5 g Trypsin (1:250). 
 2x Sample Buffer for Laemmli SDS-PAGE (Sigma#s34010). 
 Blocking buffer 
1x TBS, 0.1% Tween-20 with 5%w/v BSA. 
 Resolving gel (10%) 
 4ml acrylamide (30% 37.5:1), 3ml 1.5M Tris-HCL pH 8.8, 120μl 10% SDS, 4.8ml 
distilled water, 40μl 10% ammonium persulphate, 10μl TEMED.  
 Resolving gel (7%) 
5.84ml distilled water, 3ml 1.5M Tris-HCL pH 8.8, 3ml acrylamide (30% 37.5:1), 
120μl 10% SDS, 40μl 10% ammonium persulphate, 10μl TEMED. 
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 Stacking gel (10%) 
1.5ml acrylamide (30% 37.5:1), 2.5ml 0.5M Tris-HCl pH 6.8, 100μl 10% SDS, 5.8 ml 
distilled water, 100μl 10% ammonium sulphate, 10μl TEMED.  
 2x SDS loading buffer (stock) (2x SDS sample buffer) 
6% SDS, 20% glycerol in 0.12 M Tris-HCL pH 6.8. 
 SDS loading buffer (working) (SDS sample buffer) 
900µl 2x SDS-PAGE loading buffer, 100µl of mercaptoethanol, 50µl of 
0.08%bromophenol blue. 
 Stripping Buffer (Odyssey Infrared Imaging System)  
25mM glycine pH 2, 2% SDS. 
 Stripping buffer (ECL detection) 
30ml of water, 6ml of 10% SDS, 1875ml of 1M Tris-Hall pH6.8 and 233μl of β-
mercaptoethanol. 
 Transfer buffer 
7.575 g Tris-HCL, 36g glycine, 500ml methanol, distilled water to 2.500ml. 
 Trypsin-EDTA in HBSS without Ca²ᶧ and Mg²ᶧ (trypsin-EDTA) 
0.4g KCl, 0.06g H2PO4, 8g NaCl, 0.35g NaHCO3, 0.048g Na₂HPO₄, 1g D-glucose, 
10ml phenol red 0.1%, 2.5G TRYPSIN (1:250), 0.38G EDTA up to 1000 ml in 
distilled water.  
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 Western Transfer buffer  
7.5g Tris-HCl, 36g glycine, 500ml methanol, distilled water to 1000ml.  
 Western Wash Buffer TBS/T(500ml)  
50ml 10x TBS in 450 ml distilled water, add 0.5ml Tween-20.  
 10%Ammonium persulphate (APS) 
0.1g ammonium persulphate in 1ml distilled water.  
 10x TBS  
7.575g Tris-base, 80g NaCl, up to 1000ml distilled water, pH 7.6. 
 Wash buffer TBS/T (500ml)  
50ml 10x TBS in 450ml distilled water, 0.5ml Tween-20. 
2.1.4. Miscellaneous 
The product Producer or supplier 
BCA Protein assay kit Pierce Cramlington, UK 
Biotinylated Protein Ladder Fermenta 
Chemiluminescent agent (ECL kit) Amersham, Italy  
GeneElute Mammalian Total RNAKit Qiagen and Sigma-Aldrich  
Laemmeli Loading Buffer Biorad  
Mercaptoethanol Sigma-Aldrich  
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Odyssey blocking buffer LI-COR Biosciences  
TaqMan Gene Expression Assay Applied Biosystem 
2.2 Chemicals 
Forskolin was purchased from Calbiochem/Merck Biosciences (Nottingham. UK).  
Rapamycin Ready Made Solution, 2.5mg/mL in DMSO (2.74mM), was purchased 
from Sigma-Aldrich. 
InSolution™ AMPK Inhibitor, Compound C (1mg/250μl) solution in DMSO from 
Calbiochem/Merck Biosciences (Nottingham. UK). 
AICAR from Sigma-Aldrich. 
The following antibodies were all from cell signalling technology 
Total mTOR (7C10) Rabbit mAb (#2983), phospho-mTOR (ser2481) (#2974), 
phospho-mTOR (ser2448) (D9C2) XP® (#5536).  
Total Akt # 2938, phospho Akt Thr308 #9275 and P.Akt ser473 #9271.  
AMPKα (#23A3), Phospho-AMPKα (Thr172) (#40H9).  
p70S6 kinase (#9202), Phosph-p70S6 kinase Ser371 (#9208) and Thr389 (#9206). 
OGT Antibody (#5368), O-GLcNac (CTD110.6) was purchased from Cell New 
England Biolabs (Hitchin-UK). 
Beta-actin antibody was purchased from Abcam (Cambridge, UK).  
11βHSD2 antibody was purchased from Santa Cruz Biotechnology (California).  
IRDye 800CW Goat anti-Rabbit IgG (H + L) was from Li-Cor (UK limited). 
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The secondary horse-radish peroxidase (HRP)-conjugated immunoglobulin ` was from 
DAKO (Ely, Cambridgeenswere, UK).  
IRDye 800-conjugated goat anti-rabbit and IRDye 700-conjugated goat anti-mouse 
antibody were purchased from Rockland immunochemical.  
SYBER green Master Mix and PCR reaction mixture for quantitative RT-PCR was 
purchased from applied Biosystems (Warrington, UK).  
2.3 Cell Culture  
All techniques involving cell culture used in this research project were carried out 
aseptically in a sterile cell culture hood. Before and after each experiment, the flow 
chambers (cabinets) were sprayed with 70% ethanol and all cell culture ware were 
supplied in a sterile condition from BD Falcon. All pre-treatments and stimulations 
were carried out at 37°C in a humidified incubator at 5% CO2. Gloves were worn at 
all-times throughout cell culture procedures. Only BeWo cell line was used during this 
research project. 
2.3.1Maintenance and sub-culture of BeWo cells 
BeWo cells were cultured in F-12K Nutrient mixture Kaighn’s Modification (1X) 
liquid with L-glutamine from Gibco (Paisley, UK), with 10% fetal bovine serum 
(FBS) heat in-activated (Biosera UK, East Sussex, UK) and 1% 
penicillin/streptomycin from Sigma Aldrich which was formulated to contain 10.000 
U/ml penicillin;10 mg/ml. Aliquots were incubated at -20ºC until required. Cells were 
grown at 37°C within a humidified atmosphere at 5% CO2. The media was changed 
every other day till the cells are confluent. When cells became 70-80% confluent, they 
were then washed with pre-warmed PBS at 37ºC after aspiration of the medium. The 
washing with PBS is to remove debris and traces of FBS. Next, 2ml of trypsin 
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containing 0.02% of EDTA in HBSS without calcium was added in 75 cm² flask. The 
cells then incubated in the incubator at 37ºC for 2-3 min. When the cells detached from 
the base of the flask, which can be confirmed by observing the cells under microscope, 
7ml of pre-warmed media were added in order to neutralise the effect of trypsin 
EDTA. Cells were then transferred to 25-75cm² flask or 6-12 well plates. 
Differentiation of BeWo cells was achieved by incubating confluent undifferentiated 
BeWo cells with 100µM forskolin for 24hr, cell differentiation was monitored by 
examining the cells under light microscope for multinucleated cells. 
BeWo cells were generous gift from Dr. Jing Chen.  
2.3.2Treatment of BeWo cells  
BeWo cells were maintained in culture media as described above. Cells then seeded 
in 6-well plates for treatment. Once confluence (70-80%) was achieved, the media 
were then removed and the cells were rinsed with warm PBS. Next cells were pre-
treated with inhibitors for one hour before the cells being treated with final treatments 
(see table 2.1). Cells were treated for either 10 minutes when protein phosphorylation 
was measured; alternatively, cells were treated for 24 hours when expression of total 
proteins was measured.  
At the beginning of this work the author have treated BeWo cells with forskolin only 
at different time point (5minutes, 10minutes, 24hours and 48hours). However at 
5minutes, neither T.mTOR nor phospho-mTOR were affected by forskolin. At 10 
minutes forskolin exerts an inhibitory effect on mTOR phosphorylation at Ser2448 
and Ser2481 but it has no effect on T.mTOR. At 24 and 48 hours both Total and 
phospho-mTOR were inhibited by forskolin. I have then decided to choose the time 
point 10min (the first time point where phospho-mTOR inhibited by forskolin) to test 
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for the phospho-protein and 24hrs to test for T.protein. I have also used T.mTOR as a 
loading control for phospho-mTOR analysis, since at this time point T.mTOR is not 
inhibited by forskolin.  
Table 2.1: Treatment design of BeWo cells  
Treatment of the first 
group of BeWo cells 
Treatment of the second 
group of BeWo cells  
Treatment of the third 
group of BeWo cells 
Basal (untreated cells) Basal  Basal 
Forskolin  Forskolin  Forskolin 
Forskolin+rapamycin  Forskolin+Compound C Forskolin+AICAR 
Rapamycin  Compound C AICAR  
 
The selection of treatment concentration used in this thesis was based on previously 
published studies and manufacturer’s data. 
Forskolin 100µM was used to induce the syncytialisation process in BeWo cells 
Forskolin-diluted in DMSO at a concentration of 0.1M to final concentration of 
100µM, this is the concentration which has been shown to produce maximum 
concentration of cAMP (which is required for BeWo cells syncytialisation) within few 
minutes, and this higher concentration of cAMP can be maintained for at least 48hours 
in the presence of 100µM forskolin (Wice et al., 1990). Furthermore the use of this 
concentration was based on previously published studies (Delidaki et al., 2011, Egawa 
et al., 2008, Al-Nasiry et al., 2006).  
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Forskolin is a chemical compound isolated from the root of Plectranthus barbatus 
(Coleus Forskohlii). Forskolin was prepared at a concentration of 100µM by using 
DMSO since other solvents like ethanol inhibits the activation of adenylyl cyclase by 
forskolin (Huang et al., 1981). Furthermore, the culture media contain heat inactivated 
foetal calf serum, as the unheated one has a phosphodiesterase, the enzyme which 
degrades cAMP (Wice et al., 1990). 
The concentration for the inhibitors used in these experiments is shown in (table2.2). 
Table 2.2: Inhibitors used and their concentration and pre-incubation time 
inhibitor Form  Final concentration (M). Pre-incubation 
time (minutes) 
Rapamycin In Solution 
(DMSO) 
100nM 60  
Compound C In Solution 
(DMSO) 
10µM 60  
AICAR Powder  0.5mM 60  
 
Compound C is AMP-activated protein kinase inhibitor (AMPK) which functions as 
a key energy sensor in the cell. When it binds to AMP, it leads to its phosphorylation 
and activation by the upstream kinase, whereas its binding to ATP leads to inactivation 
of AMPK (Kimball, 2006). The mammalian target of rapamycin (mTOR) has been 
identified as one of the AMPK downstream, and it has been mentioned that there is a 
negative cross talk between mTORC1 and AMPK, since the activation of AMPK leads 
to inhibition of mTORC1 through TSC1/2 dependent or independent mechanism 
(Inoki et al., 2003).  
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5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), AICAR is frequently 
used as an activator of AMP-activated protein kinase (AMPK) which controls the 
response of the cells to energy changes and stress; its activity is also regulated by 
starvation, hypoxia, ischemia and exercise (Hardie, 2003). Inside the cell, AICAR is 
converted into the monophosphorylated nucleotide 5-aminoimidazole-4-
carboxamide-1-dribofuranosyl-5_-monophosphate (ZMP) by the enzyme adenosine 
kinase and it is similar to AMPK effect although ZMP is less potent than AMPK. 
Furthermore, ZMP does not affect the intracellular level of adenosine monophosphate 
(AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP) (Corton et al., 
1995).  
2.3.3Cells cryopreservation and revive  
To store the cells for a long period, a stock of the cells was conserved in a liquid 
nitrogen, cells were trypsinized and centrifuged at 1000 rpm for 5 minutes. Media 
were removed and the cells then re-suspended with 5ml of freezing media which 
contain 90% FBS and 10% DMSO. 1 ml of this suspension was then transferred to 
1ml cryovials (Nalgene). Vials were kept in cryofreeezing container (Fisher Scientific, 
Loughborough UK) containing isopropanol and stored overnight at -80ºC before 
transferring the vials to liquid nitrogen. To revive cells from liquid nitrogen, cells were 
warmed slightly in a water bath for 1-2 minutes, the content then mixed with pre-
warmed culture medium and then centrifuged at 1000 rpm for 4 min and re-suspended 
with 5ml of culturing media and then transferred to 25 cm² flask. The media were then 
changed after 24hrs.  
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2.3.4 Counting cells using haemocytometer 
Cells count allows an accurate platting of the cells, and to determine the cells density 
a haemocytometer was used. Chemicals used: tryptan blue (Sigma cat no T181154) 
diluted in 1:1 PBS. The tryptan blue is used to stain any dead cells which should not 
be included in the cell counting. 10ml of fresh media is put in T75 flask, following the 
removal of trypsin. Then 500µl of the cell suspension is mixed with 500µl of diluted 
tryptan blue, and then 20µl of the suspension is loaded into a haemocytometer 
chamber. Under a microscope the number of unstained cells was counted. 
Number of the cells per ml= number of cells over a large square X dilution factor X 
10000.  
2.4 Measurement of hCG secretion 
BeWo cells were cultured in 6-well plates; when they reached 70-80% confluent, cells 
were treated with the appropriate treatment at the specific concentration (Table 2.1 
and 2.2) for 24hrs. Subsequently, the supernatant was collected and centrifuged at 500 
xg for 5 min at 4°C in order to remove cell debris. All samples were then stored at -
80°C. The quantity of secreted hCG was determined by the Department of 
Biochemistry (University Hospital Coventry and Warwickshire NHS Trust) using the 
Elecsys® Intact hCG+b electrochemiluminescence immunoassay (ECLIA) and the 
fully automated modular analytics E170 testing system from Roche Diagnostics 
(Mannheim, Germany). 
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2.5 Signalling assay 
2.5.1 Preparation of soluble proteins from cultured cells for SDS-
PAGE Immunoblot Analysis 
Following treatments, cells were washed with ice-cold PBS and lysed in RIPA 
(200µLfor each well of 6-well plate), containing protease and phosphatase inhibitors. 
Culture plates were then incubated on ice for 3-5 minutes. Cells lysate were then 
transferred to 1.5 ml microcentrifuge tubes. The BCA protein assay kit (Peirce, 
Rockford, IL) was used for protein quantification. Cell lysates were then mixed with 
the calculated amount of Laemmli buffer.  
After sonication for 10 sec, cell lysates were boiled for 10 min at 97⁰C and then cooled 
on ice. Lysate then centrifuged at 10,000x g for 5 min at 4⁰C to remove cell debris and 
the supernatant was stored at -20⁰C until required. 
2.5.2 Preparation of soluble proteins from frozen placental 
fragment for SDS-PAGE 
Previously frozen placental pieces obtained from woman with gestational diabetes 
(GDM) and BMI matched controls (ethically approved) sliced and defrosted in ice-
cold lysis buffer (20mM Tris–Cl, pH7.5, 150mM NaCl, 1% Triton-X-100, 10mM 
NaF, and 1mM EDTA) supplied with 1mM Na3VO4 (Sodium orthovanadate, 1mM), 
PMSF and protease inhibitor cocktail (Santa Cruz Biotechnology, Santa Cruz, CA). 
Next, the samples were homogenized and then exposed to constant agitation at 4⁰C 
for 3hrs. Tissue lysates were then centrifuged at 4⁰C for 5 minutes. The BCA protein 
assay was used to determine the protein concentration of the supernatant. The sample 
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was then mixed with Laemmli buffer and incubated at 98⁰C for 5 minutes and then 
left on ice for 2 minutes. Sample was then stored at -20 until use. 
2.5.3 Determination of protein concentration 
The protein concentration from the cell lysate was measured using the bicinchoninic 
acid (BCA) protein assay (Pierce, Rockford, IL USA), with the bovine serum albumin 
(BSA), as reference (table 2.3). 
Table 2.3: Bovine serum albumin (BSA) standard serial dilution. 
Vial BSA Concentration (mg/ml) 
A 2 
B 1.5 
C 1 
D 0.75 
E 0.5 
F 0.25 
G 0.125 
H 0.025 
I 0 
The principle of this method is based on the reduction of Cuᶧ² to Cuᶧ¹ by bicinchoninic 
acid with the highly selective and sensitive colometric detection of the cuprous cation 
(Cuᶧ¹). The reaction involves two main stages, first is the chelation of copper with 
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protein in an alkaline environment leading to the formation of a blue coloured complex 
(Biuret reaction). In the following step, the cuprous cation (Cuᶧ¹) reacts with BCA 
reagent forming a purple coloured reaction product. The BCA/copper complex is 
water soluble and showing a strong linear absorbance at 562nm with increasing protein 
concentration. The assay was performed according to the manufacturer’s instruction. 
The standards were prepared in lysis buffer (RIPA). Standard curve was generated 
using linear regression fit with Graph Pad Prism R 4.0 software. The protein 
concentration of each sample was measured using standard curve.  
 
Figure 2.1: Standard curve obtained by using Bovine Serum Albumin (BSA) dilution 
 
2.6 Western Blotting  
Protein level in cell lysates from both treated and untreated BeWo cells was measured 
using Western blotting. Denaturation of the proteins in cell lysates made by heating at 
98ºC for 10 minutes. Lysates was then loaded into the stacking gel wells against the 
Fermentas protein marker. Equal quantities of proteins were added in each well (as 
measured by BCA assay). Electrophoresis was run at 15-20 amp, until the dye had 
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reached the bottom of the gel. The resolving gel was washed with transfer buffer 
before transfer to nitrocellulose membrane (Amersham Bioscience, Milan, Italy) .The 
samples were transferred for 60 min at 100V.  
 
 
Solution components Resolving Gel (ml) Stacking gel (ml) 
 7.5% 10% 4.5% 
Distilled H2O 5.84 4.84 5.8 
30% acrylamide mix 3 4 1.5 
1.5M Tris (pH 8.8) 3 3 - 
0.5 M Tris (pH 6.8) -  2.5 
10%SDS 0.120 0.120 0.100 
10% ammonium 
persulphate 
0.04 0.04 0.100 
TEMED 0.01 0.01 0.01 
2.6.1 Visualisation of proteins using the Odyssey Infrared Imaging 
System 
Following transfer, the nitrocellulose membrane was blocked with 10ml Odyssey 
blocking buffer (Licor-Bioscience, Cambridge, UK) for 1hr at room temperature with 
gentle agitation in order to reduce the non-specific binding of the antibody to the 
membrane. After this, the membrane is incubated with primary antibody (1:1000 
dilution) in 5% BSA overnight at 4⁰C under gentle agitation. Membrane was washed 
with 15mls of Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBS-T) three 
times 10 minutes each, before incubation in dark with secondary antibody conjugated 
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to a fluorescent dye (1:5000) in LI-COR blocking buffer. The membrane was washed 
again three times with 15 ml of TBS-T, and once with TBS, 10 min each. Finally, 
membranes were processed, proteins were identified using Odyssey Infrared Imaging 
System (Li-COR Bioscience, Cambridge, UK). Results were normalised for total 
protein or β-actin. β.actin is commonly used as a loading control in BeWo cells 
experiment and appears to give a satisfactory results (Delidaki et al., 2011, Neelima 
and Rao, 2008).  
All primary antibodies used in this project were diluted in 5% BSA in 1:1000 dilution. 
This concentration was shown to give clear bands in the membranes after 
development, with minimal non-specific signals; although higher antibodies 
concentration (1:500) was also evaluated but excessive background signals were 
observed. 
2.6.2 Stripping of membranes following Odyssey infrared imaging 
detection  
In order to re-probe membranes with various antibodies and to remove unrequired 
background signals, antibodies were stripped off by washing membranes with 
stripping buffer. The membrane was washed with 20ml of stripping buffer (25mM 
glycine buffer, pH 2, and 2% SDS) at room temperature on shaker (2X 15min). 
Membrane was blocked in Li-COR blocking buffer following two washes, 15 min 
each with TBS and then re-probed with appropriate antibody. 
2.6.3 Visualization of proteins using Enhanced 
Chemiluminescense (ECL) 
Following transfer, nitrocellulose membrane was initially blocked with TBS-T and 5 
% (w/v) BSA (Sigma-Aldrich, Willingham, UK) for 1hr at room temperature, on a 
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rolling platform. The membrane was then incubated with the primary antibody diluted 
in 10 ml of TBS-T containing 5% BSA, overnight at 4⁰C. Then, the membrane was 
washed with 15ml TBS-T (3x15min), prior to incubation with the appropriate 
horseradish peroxidase-conjugate secondary antibodies (1:2000 final dilution) for 1hr 
at room temperature. Following another washing step with TBS-T (3x15min) and two 
washes in TBS (2x15 min), proteins were visualized by exposing the membrane to X-
ray films using the ECL-plus detection system (GE Healthcare, Amersham, UK). The 
Scion Image software (Scion Corporation, Maryland, USA) was used to quantify band 
densities. Stripping of the membrane and re-probing with an anti-βactin antibody 
(1:10000) were used to confirm equal protein loading in each well (as mentioned in 
page 53). 
2.6.4 Stripping of membranes following ECL detection 
The membrane was incubated in stripping buffer (62.5mM Tris-HCL pH 6.8, 100m 
M β-mercapto-ethanol, 2% SDS) for 30 min at 55⁰C with agitation. This was followed 
by washing the membrane with TBS-T (3x15min). Then the membrane was blocked 
with a blocking buffer containing TBS-T in 5% BSA. Next, the membrane was washed 
3 times for 30 minutes with TBS-Tween (containing 0.05% tween-20) before 
incubation with blocking buffer and addition of primary and secondary antibodies, as 
mentioned above. 
2.7 Molecular biology techniques  
2.7.1 mRNA extraction  
70-80% confluent cells were plated in 6 well plates and treated with different treatment 
at the indicated concentration for 24 hr. RNase Plus mini kit (Qiagen, Crawley West 
Sussex) was used for total RNA extraction, according to manufacturer’s instruction. 
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The concentration of RNA was determined by using UV-Vis Spectrophotometer 
(NanoDrop Technologies, Wilmington, USA).  
2.7.2 RT-PCR (reverse transcription polymerase chain reaction) 
Total RNA extracted from BeWo cells was reverse transcripted into cDNA using 
RevertAid First Strand cDNA Synthesis Kit. In a total volume of 20µl, 500 ng of RNA 
was used for first strand cDNA synthesis as following: 
Firstly, 500ng RNA, 1 µl random oligo (dT) (# S0131) and RNase free H₂O up to 
12.5µl, all were mixed in sterile Eppendorf tube and heated at 65⁰C for 5min, the 
mixture was then cooled down in ice, before adding the master mix which consists of 
5X reaction buffer (4µl), RNase Inhibitor (#E00381) 0.5µl, dNTP Mix 10mM 
(#R0191) 2µl (1mM final concentration), and 1µl of RevertAid H Minus Reverse 
Transcriptase, the mixture was then incubated at 25⁰C for 5 min,42⁰C for 60 min and 
70⁰C for 10 min.  
2.7.3 Gel electrophoresis of DNA  
To further analyse the DNA, 10-20 µl of the sample with 1/5th volume of DNA loading 
buffer was loaded. Electrophoresis was carried in 1 XTBE at 80-120 V for 1-2h the 
nucleic acid then visualised under UV light. 
2.8 Polymerase chain reaction (PCR) 
In this study, SYBER Green was used for mRNA detection experiments. In this 
technique, fluorescence was detected and monitored over time during the polymerase 
chain reaction (PCR). 
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2.8.1 Quantitative real time polymerase chain reaction (RT-PCR) 
Applied Biosystem fast 7500 machine was used to perform PCR, by using SYBER 
green master mix in 20µl. Master mix was made by mixing the 1µl of forward and 
reveres primers (pre-optimized concentration), 10µl of SYBER green master mix and 
6µl of water (total volume 18µl), then added to the suitable wells depending on the 
map designed for the 96 wells plate (MicroAmp™ Fast Optical 96-Wells Reaction 
Plate, Applied Biosystems, Cat.No. 4314320) The reaction was performed in a 
triplicate with a 2µl of suitable cDNA added to each well. Plates were closed and 
centrifuged at 1000g for 1min. The machine was then adjusted to fast SYBER green. 
All samples were labelled according to wells, melting curve then added, and the plate 
was positioned inside the machine and the program was initiated. PCR conditions 
consisted of enzyme activation at 95°C for 20sec, followed by 40 cycles of 
denaturation at 95°C for 3s, 60°C for 30s, followed by melting curve analysis. 
Quantitative amounts of syncytin were calculated with reference to GAPDH using the 
comparative ΔΔCT method for relative quantification.  
However, at the beginning of this work the author have also tried ACTB as a reference 
gene along with GAPDH but the results were more satisfactory with GAPDH. 
Furthermore, in BeWo cells, GAPDH is frequently used as a reference gene in RT-
PCR experiments and seems to give a satisfactory results (Delidaki et al., 2011, 
Neelima and Rao, 2008, Pascolo et al., 2003), so the author decided to use GAPDH as 
a reference gene. 
The sequence of those genes is listed below in table 2.4 
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Table 2.4: Primer sequence used for RT-PCR analysis 
 Gene of           Forward Primer                 Reverse Primer                                                      
Interest/ 
Size                                  (5'-3')                                                    ('5-3') 
Syncytin-1         TCATATCTAAGCCCCGCAAC               TGATCTTGCAAGGTGACCAG-                                 
bp187 
Syncytin-2                   AGCAGCCGTAGTCCTTCAAA-                         AGGGGAAGAACCCAAGAGAA-                     
bp 231  
 
Figure 2.2: Melt Curves analysis from RT-PCR. A single melting peak seen for all 
samples. 
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2.9 Immunohistochemistry staining using NovoLink Max 
Polymer Detection System (500 tests) RE7150-K 
According to the manufacturer’s instruction, the following steps were followed for 
immunohistochemistry staining of previously frozen placental slides. 
The previously frozen slides was first immersed in pre-cooled acetone for 10 min to 
fix the tissue sections, and then left to dry. The slides was then washed with PBS (three 
times, 5 min each) then incubated in 0.3% peroxidase block (#RE7101) solution in 
PBS for 30min at room temperature in order to block any endogenous peroxidase 
activity. 
The slides was then washed with PBS three times, 5min each and incubated with 
protein blocking solution (#RE7102) for 1hr at room temperature. The blocking buffer 
was then poured off from the slides and the slides were washed three times 5min each 
before they were incubated with primary antibody diluted in 5% bovine serum albumin 
(BSA) overnight in cold room. Next day, the slides were washed twice in PBS 5min 
each, and then incubated with Post Primary Block for 30min (RE7111), followed by 
washing with PBS twice 5min each. The slides were then incubated with NovoLink 
polymer and secondary antibody for 30 min and next washed with PBS twice 5min 
each. To reveal the colour of the antibody staining, the slides was incubated with 
freshly made DAB solution for 5min. The slides were then rinsed with water 2 
changes, 5min each. 
The slides were then counterstained by immersing in Haematoxylin for 1-2 min and 
then washed in water for 5 min. The tissue slides were then dehydrated in alcohol 4 
changes (95%, 95%, 100% and 100%) and cleared in three changes of xylene and 
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mounted. The colour of the antibody staining in the tissue section was observed under 
microscopy. 
2.10 Data analysis and statistical methods  
In experiments of protein phosphorylation, total and phosphorylated protein levels was 
quantified using the Odyssey Infrared Imaging system or Scion image software (when 
ECL detection system was used). Background was corrected by using default settings 
and measurements of band intensities were used to obtain raw data. The resulting 
protein expression was calculated by the following formula (phosphor/total) and 
expressed as a fold change from basal, using this formula (treated/basal).  
In experiments of gene expression level, mRNA was normalized to a calibrator with 
the ΔΔCt method. Results were expressed as n-fold difference in gene expression 
relative to GAPDH The calibrator was further determined as follows: 2-(ΔCt sample 
–ΔCt calibrator) where Ct (threshold cycle) is the fractional cycle number at which the 
PCR fluorescent signal passes a specific threshold. 
The statistical analysis was carried out using Student’s unpaired t-test (which was used 
to compare two samples) or one-way ANOVA followed by the Tukey multiple 
comparison test using Prism software (GraphPad Prism, version 5.0; GraphPad Inc., 
SanDiego, CA USA). Values were considered statistically significant at P <0.05. Each 
experiment was repeated at least three times. Blots are representative of one 
experiment, and graphs represent the mean ± SEM of three independent experiments.  
Student unpaired t-test and ANOVA is commonly used to analyse data from BeWo 
cells (Madigan et al., 2010, Vatish et al., 2012). ANOVA is also commonly used to 
analysis data from RT-PCR (Brunner et al., 2004). Furthermore, the author have 
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chosen ANOVA to avoid type 1 error that result from performing multiple two sample 
t-test (statistics, 2013).  
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Results 
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Introduction 
It has been demonstrated that syncytin 1 and 2 and glial cell missing (GCM1) mRNA 
expression in trophoblast is associated with increased hCG secretion in the cell 
medium (Knerr et al., 2005). The formation of syncytium and its maintenance is one 
of the key mechanisms at the feto-maternal interface. Since understanding this process 
plays an important role in the management of pregnancy complication such as 
preeclampsia, where disturbed trophoblast fusion has been thought to be one of the 
causes (REDMAN and SARGENT, 2000). cAMP/PKA pathway plays a key role in 
up-regulation of fusogenic gene expression and the associated hCG production 
(Keryer et al., 1998, Knerr et al., 2005). The role of syncytin in inducing trophoblast 
fusion and hCG secretion has also been demonstrated by other studies which showed 
that syncytin mRNA expression was linear with cytotrophoblast differentiation and 
hCG secretion, which indicates syncytiotrophoblast formation. Furthermore, they 
found that in-vitro activation of cytotrophoblasts by cAMP is accompanied by 
increased hCG and fusogenic gene expression (Frendo et al., 2003).  
Various studies have shown that mTOR is involved in placental signaling and it acts 
as growth signaling sensor in placenta (Wen et al., 2005) and its expression is down 
regulated in IUGR (Roos et al., 2007). In addition, mTOR gene disruption in mice 
resulted in impaired trophoblast formation (Gangloff et al., 2004). Recently Vatish et 
al have shown that the process of BeWo cells differentiation and cAMP secretion is 
associated with a reduction in intracellular calcium and inhibition of PI3K/Akt 
signaling pathway (the upstream effector of mTOR signaling pathway) (Vatish et al., 
2012).  
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Based on the findings of previous studies, our study is aimed at investigating the role 
of mTOR in BeWo cells differentiation and also the effect of syncytialised BeWo cells 
on expression of mTOR and its components. 
3.1. Effect of mTOR on Forskolin-Induced BeWo Cells Fusion  
In this experiment, in order to evaluate the role of mTOR on forskolin induced hCG 
secretion in BeWo cells, the level of hCG was measured in culture media. In addition, 
the role of mTOR on forskolin induced mRNA expression of fusogenic gene as 
syncytin 1 and 2 was measured by using quantitative RT-PCR. Specific inhibitors 
were used to determine the signalling pathways involved in these effects. The 
morphological changes were assessed under a light microscope. 
In this experiment, BeWo cells were incubated with F12K media supplemented with 
10% foetal calf serum in 6-well plates; when the cells reached 70-80% confluent, 
BeWo cells then pre-treated with the inhibitors for 60 min (table 2.2), before they 
being treated with forskolin in the presence and absence of inhibitors (as shown in 
table 2.1) for 24 hr.  
The level of hCG was assessed in the media collected from treated and untreated 
BeWo cells. The quantity of secreted hCG was determined by the Department of 
Biochemistry (University Hospital Coventry and Warwickshire NHS Trust) using the 
Elecsys® Intact hCG+b electrochemiluminescence immunoassay (ECLIA) and the 
fully automated modular analytics E170 testing system from Roche Diagnostics 
(Mannheim, Germany). 
The results showed that, in forskolin-treated BeWo cells, forskolin increased hCG 
secretion by approximately 8 folds compared to basal (Figure 3.2).whereas treatment 
of BeWo cells with forskolin in the presence of either rapamycin or AICAR, resulted 
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in decreased hCG secretion by approximately 6 folds (figure 3.2 and figure3.4). 
Whereas compound C exerts no effect on forskolin-induced hCG secretion (figure 
3.3).  
Quantitative RT-PCR showed that incubation of BeWo cells with forskolin for 24h 
resulted in up-regulation of syncytin 1 and syncytin 2 mRNA expression by 
approximately 4 and 8 folds respectively (Figure.3.5). Interestingly, this effect was 
further enhanced (8 and 10 folds respectively) when rapamycin was added to 
forskolin-treated BeWo cells (figure 3.5). However, compound C (AMPK inhibitor) 
and AICAR showed no effect on forskolin induced syncytin mRNA expression 
(figure3.6 and figure 3.7.respectively).  
This might indicate that the effect of mTOR on forskolin-induced fusogenic gene 
expression is AMPK independent. In agreement with this, one study has shown that 
AMPK phosphorylation at Thr172 is essential for forskolin-stimulated tight junction 
formation in BeWo cells. They have also shown that AICAR and compound C have 
no effect on forskolin-induced cell fusion, which might indicate that AMPK is not 
implicated in this fusion process (Egawa et al., 2008, Zheng and Cantley, 2007). 
This suggests diverse and distinct actions of mTOR on the biochemical and 
morphological differentiation of BeWo cells: a positive action on the endocrine 
phenotype coupled with a negative effect on fusogenic capacity. 
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A 
 
B 
Figure 3.1: Fusion of forskolin treated BeWo cells. 
BeWo cells were studied under light microscope using a 20X objective and 
photographed digital microscope camera (Olympus, Tokyo, Japan), shows untreated 
BeWo cells (A-top) and BeWo cells after treatment with forskolin 100µM for 24h (B-
bottom). The blue arrow indicates fused cytotrophoblast cells. Scale Bar = 100µm.  
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Figure 3.2: hCG release from BeWo cells treated with forskolin with/without rapamycin 
BeWo cells were treated with either 100µM forskolin, forskolin (100µM) + rapamycin 
(100nM) or rapamycin (100nM) only for 24h. The medium was collected after 24 
hours of incubation and the level of hCG (IU/ml) released in the medium was 
determined (as described in materials and methods chapter). Data represent the mean 
± SEM of three independent experiments each analysed in triplicate *P<0.05 of 
forskolin-treated cells compared to basal, #P<0.05 of forskolin+rapamycin-treated 
cells compared to forskolin-treated cells. 
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Figure 3.3: hCG release from BeWo cells treated with forskolin with or without compound C for 
24hr  
BeWo cells were treated with 100µM forskolin, forskolin 100µM+ compound C (10 
µM) or compound C (10µM) only. The medium was collected after 24hr of incubation 
and the level of hCG (IU/ml) released in the medium was determined. Data represent 
the mean ± SEM of three independent experiments each in triplicate. *P<0.05 of 
forskolin-treated or forskolin+CC-treated BeWo cells compared with basal cells (no 
treatment).  
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Figure 3.4: hCG release from BeWo cells treated with forskolin with/without AICAR for 24h 
Level of hCG (IU/ml) released from BeWo cells treated with 100µM forskolin, 
forskolin (100µM) +AICAR (0.5mM) or AICAR (0.5mM) only. Data represent the 
mean ± SEM of three independent experiments each in triplicate *P<0.05 of forskolin 
compared with basal, #P<0.05 of forskoloin+AICAR treated cells compared to 
forskolin-treated BeWo cells.  
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Figure 3.5: Expression of syncytin 1 and 2 mRNA in BeWo cells treated with forskolin with or 
without rapamycin for 24 h 
BeWo cells were treated with forskolin 100µM in the presence or absence of 
rapamycin 100nM or rapamycin only for 24h and the expression level of targets 
mRNA was determined by RT-PCR as described in material and method chapter. 
Relative mRNA for syncytin 1 and syncytin 2 expression was normalized against the 
house keeping gene GAPDH. Data represent mean values ± SEM from three 
independent experiments each in triplicate. *P < 0.05 of forskolin-treated compared 
to basal cells. #P<0.05 (forskolin+rapamycin-treated compared to forskolin-treated 
cells).  
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Figure 3.6: Expression of syncytin 1 and syncytin2 mRNA on BeWo cells treated with forskolin 
with or without compound C. 
BeWo cells were treated with either forskolin (100µM), forskolin 100µM+compound 
C (10µM) or compound C (10µM) for 24 hr and the expression level of targets mRNA 
was determined by RT-PCR as described in material and method, relative mRNA 
expression was normalized against the house keeping gene (GAPDH) Data represent 
mean values ± SEM from three independent experiments. *P < 0.05 of forskolin 
treated cells compared with basal (untreated cells).  
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Figure 3.7: Expression of syncytin 1 and syncytin2 mRNA in BeWo cells treated with forskolin 
with or without AICAR. 
BeWo cells were treated with either forskolin (100µM) or forskolin (100µM) 
+AICAR (0.5mM) or with AICAR only for 24hr and the expression level of targeted 
mRNA was determined by RT-PCR as described in material and method, relative 
mRNA expression was normalized against the house keeping gene (GAPDH) Data 
represent mean values ± SEM from three independent experiments each in triplicate. 
*P < 0.05 of forskolin treated compared with basal (untreated cells). 
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3.2. Effect of mTOR on forskolin induced 11βHSD2 expression  
11-βHSD2 is NAD dependent enzyme and is present mainly in kidney, placenta and 
pancreas (Krozowski et al., 1995). Most of foetal glucocorticoids originate from the 
mother and the placental enzyme 11βHSD2 converts active cortisol to inactive 
cortisone. This action is very important in placenta which allows 11-βHSD2 to act as 
a protector that prevent the passage of maternal glucocorticoid to the foetus (Edwards 
et al., 1988). In placenta 11βHSD2 is expressed mainly in syncytiotrophoblst 
(Krozowski et al., 1995).  
Even though glucocorticoids are essential for intrauterine foetal growth and 
development, excessive intrauterine exposure to glucocorticoids can cause intrauterine 
growth restriction and could lead to hypertension and diabetes mellitus in adult life 
(Seckl, 2001).  
The effect of mTOR on 11βHSD2 enzyme production by BeWo cells was also 
investigated by applying Western immunoblotting in cell lystaes from treated (for 24h) 
and untreated BeWo cells (see table 2.1) 11βHSD2 specific antibody was used. 
Results showed that the treatment of BeWo cells with forskolin resulted in 
approximately 7 folds increase in 11βHSD2 secretion (figure 3.8).  
However, neither rapamycin nor compound C affects forskolin-stimulated 11βHSD2 
secretion (figures 3.8 and 3.9). Whereas AICAR has a negative effect on forskolin-
induced 11βHSD2 secretion by BeWo cells (Figure 3.10). The results might indicate 
that mTOR pathway has no effect on 11βHSD2 secretion by BeWo cells, and the 
inhibitory effect of AICAR on 11βHSD2 secretion could be through mTOR 
independent pathway. 
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Figure 3.8: Expression of 11βHSD2 in BeWo cells treated with forskolin with or without 
rapamycin. 
BeWo cells were treated with the indicated treatment. The expression level of 
11βHSD2 was measured in BeWo cell lysate by Western immunoblotting using the 
ECL Western blotting detecting reagent (VMR, UK) for protein visualisation. Result 
were normalised for β.actin. Blots are representative. Data represent the mean ± SEM 
of three independent experiments. *P < 0.05 forskolin-treated compared to basal. # 
P<0.05 of forskolin+rapamycin treated cells compared to rapamycin treated cells.  
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Figure 3.9: Expression of 11βHSD2 in BeWo cells treated with forskolin with or without 
compound C. 
BeWo cells were treated with forskolin with or without compound C as indicated for 
24h. The expression level of 11βHSD2 was measured in BeWo cell lysate by Western 
immunoblotting using the Odyssey detection system. Results were normalised for 
β.actin. Data represent the mean ± SEM of three independent experiments. Blots are 
representative *P<0.05 (forskolin-treated compared to basal cells) #P<0.05 
forskolin+compound C-treated compared to compound C-treated cells. 
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Figure 3.10: Expression of 11βHSD2 in BeWo cells treated with forskolin with or without AICAR. 
BeWo cells were treated with forskolin with or without AICAR as indicated for 24h. 
The expression level of 11βHSD2 was measured in BeWo cell lysate by Western 
immunoblotting using the Odyssey detection system. Results were normalised for 
β.actin. Data represent the mean ± SEM of three independent experiments. *P < 0.05, 
(forskolin-treated compared to basal), #P<0.05 (forskolin+AICAR-treated compared 
to forskolin-treated cells). 
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3.3. Effect of BeWo cells differentiation on expression of mTOR 
and its related components  
Our previous finding led us to investigate the effect of forskolin-driven adenylyl 
cyclase activation and intracellular cAMP production on mTOR expression and 
activity. 
To measure the expression of P.mTOR (Ser-2448/2481), total mTOR, P.Akt (Ser473) 
and P.p70s6k (Ser371 and Thr389), I applied a western blot analysis on treated and 
untreated BeWo cells. BeWo cells were treated for 10 min when protein 
phosphorylation was measured, since the process of phosphorylation usually takes few 
minutes to start, however, when total protein was measured, BeWo cells were 
incubated with treatment for 24 hr as was previously explained in chapter 2 (2.3.2 
Treatment of BeWo cells). 
I found that forskolin almost eliminates phosphorylation of mTOR at Ser-2448 and 
2481, and these effects were maintained when either rapamycin or AICAR was added 
to forskolin-treated BeWo cells (figure3.11 and 3.14 respectively). However, 
compound C showed no effect on mTOR phosphorylation at ser2448 at 10min. 
(figure3.12). However, when I tested the effect of compound C on P-mTOR (Ser2448) 
at 24h it showed up-regulation of phosphorylation at Ser2448, whereas the inhibitory 
effect of forskolin on mTOR phosphorylation was maintained even at 24hr 
(figure3.13).  
Forskolin also inhibited the expression of T.mTOR (Figure 3.15), and this inhibitory 
effect was maintained when either rapamycin or AICAR were used with forskolin in 
treating BeWo cells (Figure 3.15. figure 3.17). However, the addition of compound C 
to forskolin-treated BeWo cells resulted in up-regulation of T.mTOR expression 
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(figure 3.16). Collectively, these results showed that forskolin almost eliminates 
mTOR expression and phosphorylation.  
To further investigate the effect of forskolin-induced BeWo cells differentiation on 
mTOR signalling pathway, I have tested the effect of forskolin on Akt (Ser473) 
phosphorylation. The results showed that forskolin inhibits Akt phosphorylation at 
Ser473 within 10 minutes of treatment (Figure 3.18). Akt (Ser473) is mTORC2 
substrate and when activated, it resulted in up-regulation of mTORC1 signalling 
pathway, this indicates that forskolin inhibits the upstream stimulator of mTORC1 as 
well as its downstream effectors (P.p70s6k Thr389).  
The addition of either rapamycin, or AICAR (figure3.18, 3.20) to syncytialised 
(forskolin-treated) BeWo cells resulted in no change in the inhibitory effect of 
forskolin, on Akt phosphorylation. However, treatment of BeWo cells with rapamycin 
alone resulted in up-regulation of Akt phosphorylation (figure 3.18), and this 
activation could be indirectly through mTORC2, since rapamycin also inhibits 
P.p70s6k which exerts a negative feedback effect on mTORC2. It has also been 
observed that rapamycin can lead to an early transitory increase in Akt the effect that 
was explained due to the up-regulation of IRS1 (insulin receptor substrate1) which 
stimulates PI3K pathway and consequently phosphorylate Akt at Ser473 (O'Reilly et 
al., 2006).  
Forskolin exerts inhibitory effect on p70s6k phosphorylation at Thr389 (the direct 
downstream effector of mTORC1) (figure 3.21), and this inhibitory effect might be 
due to inhibition of mTOR phosphorylation by forskolin. Rapamycin also inhibited 
p70s6k phosphorylation at Thr389 (figure 3.21), whereas treating BeWo cells with 
compound C alone resulted in up-regulation of P.p70s6k (Thr389) (figure 3.22).  
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The experiment has also shown that forskolin stimulates P.p70s6k phosphorylation at 
Ser371 (figure 3.23); this effect is inhibited when either rapamycin (figure3.23), 
compound C (figure 3.24) or AICAR (figure3.25) were used with forskolin in treating 
BeWo cells.  
I have also measured the expression of P.AMPK (Thr172) in order to know if the 
effect of forskolin on mTOR expression and phosphorylation is AMPK dependent. 
The results showed that, forskolin has no effect on AMPK phosphorylation (at 10min) 
even when either rapamycin (figure 3.26) or AICAR (figure 3.28) was used with 
forskolin in treating BeWo cells. However, the addition of compound C to forskolin-
treated BeWo cells resulted in inhibition of AMPK phosphorylation (10min) (figure 
3.27). 
AICAR is AMPK stimulator and since AICAR produced no effect on AMPK 
phosphorylation at 10 min (figure 3.28), I treated BeWo cells again with either 
forskolin, forskolin+AICAR or AICAR only for 24h. Interestingly, at 24hr, AICAR 
stimulated AMPK phosphorylation at (Thr172) (figure 3.29). 
At 24h forskolin showed no effect on AMPK phosphorylation, and this is 
contradicting the results showed by (Egawa et al., 2008) who have found that long 
term treatment (>12hr) of BeWo cells with forskolin stimulates AMPK 
phosphorylation at Thr172. However, they also noticed that forskolin has no effect on 
AMPK phosphorylation on short term treatment (<12h). This might indicate that 
forskolin-induced inhibition of T.mTOR at 24hr is AMPK independent. The results 
showed that inhibitory effect of compound C on AMPK phosphorylation can be 
demonstrated at 10 min  (figure 3.27) whereas the stimulatory effect of AICAR on 
AMPK phosphorylation can be demonstrated at 24h (figure 3.29). 
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3.3.1.  Expression of P.mTOR (Ser2448/2481) expression  
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Figure 3.11: Expression of phospho-mTOR (Ser2448 and Ser2481) in BeWo cells treated with 
forskolin with or without rapamycin (10 minutes). 
Phosphorylation levels of target proteins were detected in cell lysates using specific 
primary phospho-antibody. Antibody for total mTOR was used as loading control. 
ECL Western blotting detecting reagent (VMR, UK) was used for protein 
visualization. Blots are representative and data represent the mean ± SEM of three 
independent experiments, quantified against total protein (P/T).*P < 0.05 of treated 
BeWo cells compared to basal (untreated).  
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Figure 3.12: Expression of phospho-mTOR (Ser2448 and Ser2481) in BeWo cells treated with 
forskolin with or without compound C (CC) for 10 min. 
Cells were treated with forskolin (100µM), forskolin (100nM) + compound C (10µM), 
or compound C only (10µM) for 10min then phosphorylation of target proteins was 
detected in cell lysates using immunoblotting. Antibody for total mTOR was used as 
loading control, Odyssey system was used for protein visualization. Blots are 
representative and data represent the mean ± SEM of at least three independent 
experiments. *P < 0.05 of treated cells compared to basal, # P<0.05 (forskolin+CC 
compared to forskolin treated cells).  
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Figure 3.13: Expression of phospho-mTOR (Ser2448) in BeWo cells treated with forskolin with 
or without compound C (CC).  
BeWo cells were treated with the indicated treatment for 24h and phosphorylation 
levels of target proteins were detected in cell lysates using specific primary phospho-
mTOR (Ser2448) antibody. Antibody for total mTOR was used as loading control. 
Blots are representative and data represent the mean ± SEM of three independent 
experiments quantified against total protein (P/T).*P < 0.05(forskolin and compound 
C treated cells compared to untreated cells), #P<0.05(forskolin+compoundC treated 
cells compared to basal cells).  
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Figure 3.14: Expression of phospho-mTOR (Ser2448 and Ser2481) in BeWo cells treated with 
forskolin with or without AICAR for 10 min. 
Cells were treated with either forskolin 100nM, forskolin (100µM) +AICAR (0.5mM) 
or AICAR (0.5mM) for 10min then phosphorylation levels of target proteins was 
measured. Odyssey infrared system and ECL Western blotting detecting reagent 
(VMR, UK) were used for protein visualization, data represent mean ± SEM of three 
independent experiments. Bar graphs represent fold increase relative to basal 
conditions. *P<0.05 of treated BeWo cells compared to basal. 
83 
 
B
as
al
Fo
rs
ko
lin
Fo
rs
ko
lin
+R
ap
a
R
ap
a
0.0
0.5
1.0
1.5
R
a
ti
o
 o
f 
T
.m
T
O
R
/
.a
c
ti
n
(f
o
ld
s
 c
h
a
n
g
e
 f
ro
m
 b
a
s
a
l)
T.mTOR
.actin
Forskolin (100M)              -           +          +          -
Rapamycin(100nM)            -            -          +          +
*
*
*
289kD
42kD
 
Figure 3.15: Expression of total mTOR in BeWo cells treated with forskolin with or without 
rapamycin for 24 h. 
BeWo cells were treated with the indicated treatment for 24hr next, the expression 
levels of total proteins was detected in cell lysates using immunoblotting. Antibody 
for β-actin was used as a loading control, data represent mean ± SEM of at least three 
independent experiments. Bar graphs represent fold change compared to basal, 
*P<0.05 (treated BeWo cells compared to basal). 
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Figure 3.16: Expression of total mTOR in BeWo cells treated with forskolin with or without 
Compound C. 
Cells were treated with the indicated treatment for 24hr, then the expression levels of 
total proteins were detected in cell lysates using immunoblotting. Data represent mean 
± SEM of three independent experiments (*P <0.05forskolin and compound C treated 
BeWo cells compared to basal), #P<0.05 (forskolin+CC treated cells compared to 
forskolin treated cells). 
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Figure 3.17: Expression of total mTOR in BeWo cells treated with forskolin with or without 
AICAR for 24h. 
Cells were treated with the indicated treatment for 24hr., then the expression levels of 
T.mTOR proteins were detected in cell lysates using immunoblotting, data represent 
the mean ± SEM of three independent experiments, Bar graphs represent folds change 
from basal (*P<0.05 of treated BeWo cells compared to basal). 
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3.3.2. Expression of PAkt (Ser473) in BeWo cells 
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Figure 3.18: Expression of P.Akt in BeWo cells treated with forskolin with or without 
rapamycin.for 10 min. 
BeWo cells were treated with forskolin (100mM) with or without rapamycin (100nM) 
for 10min, the expression of P.Akt (Ser473) was determined by immunoblotting using 
the Odyssey detection system for protein visualization. Total Akt was used as a 
loading control. Data represent the mean ± SEM from three independent experiments.* 
P<0.05(treated BeWo cells compared to basal). 
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Figure 3.19: Expression of P.Akt in BeWo cells treated with forskolin with or without compound 
C 
BeWo cells were treated with the indicated treatment for 10 min. The expression of 
PAkt (ser473) was determined in treated and untreated BeWo cells using western 
immunoblotting. Data represent the mean ± SEM from three independent experiments 
and bar graph represent the folds of changes from basal. Blots are representative. * 
P<0.05 (forskolin treated cells compared to basal).  
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Figure 3.20: Expression of P.Akt in BeWo cells treated with forskolin with or without AICAR. 
Cells were treated with forskolin (100mM) with or without AICAR (0.5mM) for 10 
min, P.Akt expression was determined by immunoblotting using the Odyssey 
detection system for protein visualisation. Data represent the mean ± SEM from three 
independent experiments. * P<0.05 treated cells compared to basal. 
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3.3.3. Expression of P.p70s6k (Ser371 and Thr389)  
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Figure 3.21: Expression of p70s6k (Thr389) in BeWo cells treated with forskolin with or without 
rapamycin (10min). 
Western immunoblot detecting the expression of P.p70s6k (Thr389) in treated and 
untreated BeWo cells. Blots are representative and data are presented in mean ± SEM 
of three independent experiments. *P<0.05 of treated cells compared with basal. 
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Figure 3.22: Phosphorylation of p70s6k (Thr389) in BeWo cells treated with forskolin with or 
without compound C (10µM) for 10 min. 
Cell lysates were prepared from treated and untreated BeWo cells and target proteins 
were assayed on western blot. Blots are representative and data are presented as mean 
± SEM of at least three independent experiments. *P<0.05 of forskolin treated and 
compound C-treated cells compared to basal. #P<0.05 forskolin+compound C-treated 
cells compared to forskolin-treated cells. 
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Figure 3.23: Expression of P.p70s6k (Ser371) in BeWo cells treated with forskolin with or without 
rapamycin (100nM) for 10 min. 
Cell lysates were prepared from treated and untreated BeWo cells and target proteins 
were assayed on western blot. Total P70S6K was used as a loading control. Data are 
presented as mean ± SEM of three independent experiments. *P<0.05 (rapamycin 
treated and forskolin treated BeWo cells compared to basal). #P<0.05 
(forskolin+rapamycin treated cells compared to forskolin treated cells). 
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Figure 3.24 : Phosphorylation of p70s6k (Ser371) in BeWo cells treated with forskolin with or 
without compound C (10min.). 
Cells were treated with the indicated treatment for (10mins). Western blotting was 
used for measurement of p70s6k phosphorylation (Ser371). Blots are representative 
and data represent the mean ± SEM of three independent experiments.*P<0.05 
(forskolin treated compared to untreated cells) #P<0.05 (forskolin+CC treated cells 
compared to forskolin treated cells). 
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Figure 3.25: Phosphorylation of p70s6k (Ser371) in BeWo cells treated with forskolin with or 
without AICAR (10 min). 
BeWo cells were treated with the indicated treatment for 10 min. Cell lysates were 
prepared and the expression of P.p70s6k (Ser371) was assayed on western blot. Total 
P70S6K was used as a loading control. Blots are representatives and data are presented 
in mean± SEM of three independent experiments. *P<0.05 (treated compared to 
basal), #P<0.05(Forskolin + AICAR-treated compared to Forskolin-treated BeWo 
cells).  
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3.3.4. Expression of P.AMPK (Thr172) 
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Figure 3.26: Expression of P.AMPK (Thr172) in BeWo cells treated with forskolin with or 
without rapamycin (10 min). 
Expression of P.AMPK (Thr172) was measured on western blot. Total AMPK was 
used as a loading control and odyssey infrared system was used for protein 
visualization. Blots are representative. Data are presented in mean ± SEM of three 
independent experiments. 
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Figure 3.27: AMPK phosphorylation in BeWo cells treated with forskolin with or without 
compound C (CC) for 10min.  
Measurement of AMPK phosphorylation in treated and untreated BeWo cells using 
Western immunoblotting. Blots are representative and data are presented in mean ± 
SEM of three independent experiment. *P<0.05 of treated cells compared with basal. 
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Figure 3.28: AMPK phosphorylation in BeWo cells treated with forskolin with or without AICAR 
(10 min). 
Cell lysates were prepared and the expression of P.AMPK (Thr172) was measured 
using western blot. Total AMPK was used as a loading control. Blots are 
representative and data are presented in mean ± SEM of three independent 
experiments. 
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Figure 3.29: Expression of P.AMPK in BeWo cells treated with forskolin with or without AICAR 
for 24h. 
Cells were treated with the indicated treatment for (24h). Cell lysates were prepared 
and AMPK phosphorylation was assayed by western immunoblotting. Total AMPK 
was used as a loading control Data are presented in a mean ± SEM of three independent 
experiments and blots are representative.*P<0.05 of treated cells compared to basal. 
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3.4. Expression of mTOR and it is related component in normal 
and GDM placenta 
Our previous findings (which suggested the involvement of mTOR in the processes of 
BeWo cells differentiation) and the results of a previous study conducted by Jansson 
et al that have shown increased expression of mTOR signalling pathway in placenta 
from obese pregnant women, characterised by increased insulin resistance (Jansson et 
al., 2013). And because insulin is the upstream activator of Phosphatidylinositol 3-
kinase (PI3K) which controls most of the metabolic actions of insulin, and it also 
activates mTORC1 through Akt (Taniguchi et al., 2006), all these prompt me to 
investigate the hypothesis that mTOR signalling is activated in the placenta from the 
mothers with GDM compared to normal pregnant women.  
I measured the expression and activity of 11βHSD2, mTOR and its related compounds 
in GDM placentas and compared normal placentas. Tissue lysates were prepared from 
previously frozen placentas obtained from GDM patients and BMI matched controls 
(as described in materials and methods 2.5.2). Five GDM (BMI >30) and 6 matched 
controls were used. The demographics of the women from both group are presented 
in table 3.1.  
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Table 3.1: Biometric characteristics between normal and GDM pregnant women 
characteristic Normal (n=6) 
Mean 
GDM (n=5) 
Mean 
Age (years) 28.8(22-34) 31.5(27-36) 
BMI (kg/m²)  24.4 (23.5-26.8) 
 
34.5 (32.9-36.3) 
 
Gestational age 
(weeks) 
39.4 (38-41) 
 
38.(37-39) 
 
 
I applied Western immunoblotting on placental lysates to measure the expression of 
mTOR and its related components. I also compared the expression of 11β-HSD2 in 
GDM compared to normal placenta. 
The results showed increased expression of 11βHSD2 protein in placenta from GDM 
by 2 folds (figure 3.30). The expressions of T.mTOR and P.mTOR (Ser2448/2481) 
were also increased in GDM compared to control (figure 3.31). In addition, the 
expressions of P.p70s6k (Ser371 and Thr389) were both increased in GDM placenta 
compared to control (Figure3.32).  
Furthermore, the expression of phospho-Akt (Ser473), which is the indicator of 
mTORC2 activity, is increased in GDM placenta compared to control (Figure 3.33). 
However, there was no significant difference in the expression of P.Akt (Thr308) in 
GDM compared to normal placenta (Figure 3.33). P.Akt (Thr308 and Ser473) 
represent the upstream activator of mTOR signalling pathway The expression of 
P.AMPK (Ser172) in GDM placenta was lower than in normal placenta (figure 3.34).  
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Immunohistochemistry showed increased staining of mTOR and P.mTOR 
(Ser2448/2481) in GDM placenta, compared to control (figures 3.35, figure3.36 and 
figure 3.37). 
 
3.4.1. Expression of 11βHSD2 in normal and GDM placentas 
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Figure 3.30: Expression of 11β HSD2 in normal (N) and GDM (D). 
Placental lysates were prepared from previously frozen normal and GDM placentas as 
mentioned in the material and method, and the target proteins were assayed on western 
blot using the Odyssey detection system for protein visualization. β.actin was used as 
a loading control. Data represent the mean ± SEM of three independent 
experiments.*P < 0.05 GDM compared with normal. 
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3.4.2. Expression of total and phospho-mTOR (Ser2448/2481) 
in normal and GDM placentas  
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Figure 3.31: Expression of total and P.mTOR (Ser2448 and Ser2481) in normal (N) and GDM 
placenta 
Placental lysates were prepared from previously frozen normal and GDM placenta, 
and target proteins were assayed on western blot using the Odyssey detection system. 
T.mTOR was used as a loading control for P.mTOR (Ser2448 and Ser2481) and β 
actin was used as a loading control for T.mTOR. Blots are representative and data 
represent the mean ± SEM of three independent experiments. *P<0.05 GDM 
compared with normal. 
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3.4.3. Expression of P.p70sk (ser371 and Thr389) in normal 
and GDM placenta 
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Figure 3.32: Expression of P.p70s6k (Ser371 and Thr389) in normal (N) and GDM placenta. 
Placental lysate were prepared from previously frozen normal and diabetic placenta 
target proteins were assayed on western blot using the Odyssey detection system. Total 
p70s6k was used as a loading control. Data represent the mean ± SEM of three 
independent experiments. *P < 0.05 GDM compared with normal. 
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3.4.4. Expression of P.Akt (Ser473 and Thr308) in normal and 
GDM placentas: 
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Figure 3.33: Expression of PAkt (Ser473 and Thr308) in normal (N) and GDM placenta. 
Placental lysates were prepared from previously frozen normal and GDM placenta, 
and target proteins were then assayed on western blot using the Odyssey detection 
system. T.Akt was used as a loading control. Blots are representative and data 
represent the mean ± SEM of three independent experiments. *P < 0.05 GDM 
compared with control. 
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3.4.5. Expression of P.AMPK (Thr172) in normal and GDM 
placentas 
no
rm
al
G
D
M
0.0
0.5
1.0
1.5
 N           GDM
P.AMPK(Thr172)
T.AMPK
*
62kD
62kD
R
a
ti
o
 o
f 
P
.A
M
P
K
 (
T
h
r1
7
2
)/
T
.A
M
P
K
c
o
m
p
a
re
d
 t
o
 n
o
rm
a
l
 
Figure 3.34: Expression of P.AMPK in normal (N) and GDM placenta. 
The target proteins were assayed on western blot using the Odyssey detection system 
for protein visualization. T.AMPK was used as loading control. Data represent the 
mean ± SEM of three independent experiments.*P < 0.05 GDM compared with 
normal. 
105 
 
3.4.6. Immunohistochemistry: phospho-mTOR (Ser2448) 
staining in normal and GDM placentas 
 
Figure 3.35: Immunohistochemistry of P.mTOR (Ser2448) staining in human normal (top) and 
GDM (bottom) placentas.  
Placental staining of phospho-mTOR (Ser2448) (D9C2) XP Rabbit mAb in 1:200 
performed on serial sections of placenta as described previously in material and 
methods. P.mTOR staining was higher in GDM compared to control. Most of the 
staining located in cytotrophoblasts (arrows). 
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3.4.7. Immunohistochemistry: phospho-mTOR (Ser2481) 
staining in normal and GDM placentas 
 
 
Figure 3.36: Immunohistochemistry of P.mTOR (Ser2481) staining in human normal (top) and 
GDM (bottom) placentas. 
Placenta; staining  of Phospho-mTOR (Ser2481) antibody (#2974) in 1:200 dilution, 
performed on serial sections as described previously in material and methods. 
.P.mTOR staining was higher in GDM compared to control. Most of the staining 
located in cytotrophoblast (arrows).  
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3.4.8. Immunohistochemistry: T.mTOR staining in normal and 
GDM placentas 
 
 
 
Figure 3.37: Immunohistochemistry of T. mTOR staining in human normal (top) and GDM 
(bottom) placentas 
This is performed on serial sections of placenta as described previously in material 
and methods, Anti-mTOR antibody (ab2732) was used as primary antibodies with 
1:200 dilution. T.mTOR staining was higher in GDM compared to control. Most of 
the staining located in cytotrophoblast (arrow).  
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3.5. Expression of OGT and O-GLcNAc protein in BeWo cells and 
placenta 
Introduction  
The deleterious effect of hyperglycaemia involves different mechanisms, among those 
is the O-GlcNac Glycosylation (O-GlcNAclation) (Alejandro et al., 2014) which 
consists of adding of a single N-acetylglucosamine (GlcNAc) to serine or threonine 
residues of proteins in the nucleus and cytoplasm. It is a posttranslational modification 
and unlike other glycosylation events which occur in Golgi bodies or in endoplasmic 
reticulum. It is a reversible process and is regulated by the enzymes O-GlcNAc 
transferase (OGT) which catalyse the addition of O-GlcNAC, and N-
acetylglucosaminidase (O-GlcNAcase) which catalyse the removal of O-GlcNAC 
(Walgren et al., 2003). The highest concentration of O-GLcNAc occur in nuclear 
protein (Hanover et al., 1987). O-linked N-acetylglucoseamine (O-GlcNAc) was first 
discovered in early 1980s (Torres and Hart, 1984). Nearly 500 proteins of important 
cellular processes were identified as an O-linked N-acetylglucoseamine target. O-Glc-
Nac is linked to various human diseases, an increased O-Glc-Nac level has been linked 
to the aetiology of insulin resistance, hyperglycemia and metabolic abnormalities 
(Park et al., 2010). Through hexosamine biosynthetic pathway (HBP) 2-3% of glucose 
in β-cells is used for the synthesis of uridine diphosphate-N-acetylglucosamine (UDP-
GlcNAc), which acts as an OGT substrate. (Alejandro et al., 2014). 
It is well known that GDM induces hyperglycaemic environment in the placenta 
(Rudge et al., 2011) that resulted in increased activity of hexamine biosynthesis 
pathway and in turn increased O-GlcNAcylation (Alejandro et al., 2014). Based on 
this and the role of the O-Glc-Nacylation in pathology of insulin resistance, and the 
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increased expression of mTOR in GDM. I hypothesized that mTOR is involved in O-
GlcNAcylation and my aims in this experiments are: 
 To compare the expression of O-GlcNAc and OGT proteins in GDM placenta with 
normal placenta. 
 To compare the expression of O-GlcNAc and OGT proteins in normal placenta with 
BeWo cells. 
 To compare the expression of O-GlcNAc and OGT proteins between untreated and 
rapamycin treated BeWo cells cultured in normal (7mM) or in high (20mM) glucose 
media. 
3.5.1. Expression of O-GlcNac and OGT protein in normal and 
GDM placentas 
In this experiment, western immunoblotting was applied using cell lysates prepared 
from normal placenta and GDM placentas (as explained in materials and methods), 
specific O-GlcNAc and OGT antibody were used. 
The result showed increased expression of O-GlcNAC and OGT protein in GDM 
placentas compared to control (Figure 3.38). 
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Figure 3.38: Expression of OGlcNAc and OGT proteins in normal (N) and GDM placentas. 
Placental lysates were prepared from previously frozen normal and GDM placenta. 
OGlcNAc (A) and OGT (B) proteins were assayed on western blot using OGlcNAc 
and OGT specific antibody. The Odyssey detection system was used for protein 
visualization. Blots are representative. The data represent Mean ± SEM of three 
independent experiments. *P < 0.05 GDM compared to normal.  
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3.5.2. Expression of O-GlcNac protein in BeWo cells and 
normal placenta  
BeWo cell lysates and placental lysates were prepared and subjected to Western 
immunoblotting for the measurement of OGT and O-GlcNac protein expression. The 
result showed decreased expression of OGT and O-GlcNac proteins in normal 
placenta compared to BeWo cells (figure 3.39). 
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Figure 3.39: Expression of OGlcNAc and OGT proteins in BeWo cells and normal (NP) placentas. 
Lysates were prepared from BeWo cells and normal placenta (as mentioned in 
materials and methods chapter),O-GlcNac(A) and OGT (B), proteins were assayed on 
western blot using O-GlcNAc and OGT specific antibody the Odyssey detection 
system was used for protein visualization. The data represents Mean ± SEM of three 
independent experiments. *P<0.05 NP compared to BeWo cells. 
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3.5.3. Expression of O-GlcNac and OGT protein in BeWo cells 
treated or untreated with rapamycin (100nM) and cultured 
in F12K media with normal (7mM) or high (20mM) glucose 
concentration for 48hr 
In this experiment, BeWo cells were cultured in F12K medium contains 7mM glucose 
(this is the normal glucose concentration contained in F12K media which is used for 
BeWo cells culture); when the cells were 70% confluent, media were changed and 
BeWo cells were incubated in media with either normal glucose concentration (7mM) 
with or without rapamycin (100nM), or with high glucose concentration (20mM) with 
or without rapamycin 100nM) for 48hr. Following incubation, cell lysates were 
prepared from treated and untreated BeWo cells and processed for SDS-PAGE 
electrophoresis.  
For the high glucose concentration; two different concentration of glucose was tried 
by the author (20mM and 25mM), since those concentrations was considered to be the 
hyperglycemic condition in term placenta trophoblast and BeWo, JAR and JEG-3 cells 
(Weiss et al., 2001, Hahn et al., 1998). At the 25mM concentration, the growth of the 
cells was not satisfactory. Consequently and after preliminary testing the decision to 
fix the glucose concentration at 20mM was made. 
The result showed that, the overall expressions of O-GlcNac and OGT proteins were 
higher in untreated BeWo cells compared to rapamycin treated BeWo cells. The 
expression was also higher in BeWo cells, which were cultured in high glucose media 
compared with the cells cultured in normal media. (Figures 3.40 and 3.41). 
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3.5.3.1. Expression of O-GlcNac and OGT protein in BeWo cells 
treated or untreated with rapamycin and cultured in normal 
media (with 7mM) or high glucose media (20mM) for 48 h. 
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Figure 3.40: Expression of OGlcNAc and OGT protein in BeWo cells treated or untreated with 
rapamycin and cultured in normal media or high glucose media. 
Lysates were prepared from BeWo cells treated or untreated with rapamycin and 
cultured in normal glucose media or high glucose media for 48h and O-GlcNAc and 
OGT protein expression from both group were assayed using western immunoblotting 
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The graph represent Mean ± SEM of three independent experiments.*P<0.05 of 
rapamycin treated cells compared to basal. 
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General Discussion and Conclusion 
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Discussion  
It is well recognised that cAMP and mTOR signalling pathways control important 
cellular processes such as proliferation, metabolism, and protein synthesis and cell 
survival. Thus, understanding the pathway that joins the two signalling is very crucial 
(Xie et al., 2011). Despite its role in cancer, there is no enough data regarding the 
effect of mTOR signalling pathway on gestational trophoblastic diseases (GTDs) 
(Mparmpakas et al., 2010). GTDs is a group of diseases affecting placenta and consists 
of complete hydatidiform mole, invasive mole, placental site trophoblastic tumour and 
choriocarcinoma (Fulop et al., 2004). The role of mTOR signalling pathway in 
trophoblast cell differentiation and proliferation is still not fully known (Wen et al., 
2005). Researchers have shown that mTOR is important for early embryo growth and 
proliferation. They reported that mTOR lacking embryos die after implantation due to 
impaired cell proliferation (Vargas et al., 2009, Gangloff et al., 2004). 
In BeWo cells, many pathways have shown to be involved in hCG secretion and 
fusogenic gene expression. For example, cAMP/PKA pathway plays a major role in 
trophoblast differentiation (Keryer et al., 1998). Furthermore, ERK1/2 and p38 MAPK 
pathways, the activated down stream of adenylyl cyclase, have been demonstrated to 
play distinct roles in fusogenic gene expression and hCG secretion ((Delidaki et al., 
2011)). A decrease in syncytin 1 expression may be associated with the development 
of complication during pregnancy as it has been reported by previous study (Wilson 
et al., 2003), where they found an association between the development of 
preeclampsia and HEELP syndrome and a decrease in syncytin 1 expression.  
Fusion of cytotrophoblast is not just associated with morphological changes, but it is 
also characterised by changes in trophoblast transport and endocrine activities 
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(Pötgens et al., 2002). The relationship between mTOR protein and hCG hormone has 
been demonstrated in various studies. One study has reported that hCG up regulates 
mTOR kinase signalling pathway in theca interstitial cells, (Palaniappan and Menon, 
2010), while in granulosa cells in ovulating follicle in mice, inhibition of hCG resulted 
in down regulation of mTOR kinase activity (Siddappa et al., 2014). 
Researchers have found that a combination of a calcium channel inhibitor and 
PI3K/Akt inhibition augmented forskolin-induced BeWo cell fusion. However, 
inhibition of P13K/Akt pathway alone was not enough to stimulate BeWo cell fusion. 
This indicates that many signalling pathways are involved in processes of BeWo cells 
syncytjalization (Vatish et al., 2012). Therefore, the aims of this work were to 
investigate the role of mTOR in fusogenic gene expression and hCG secretion by 
syncytialised BeWo cells and the effect of BeWo cells differentiation on expression 
of mTOR and its related components. In addition, I investigated the expression and 
activity of mTOR in placentas obtained from gestational diabetes (GDM) patients and 
BMI matched controls. 
For the purpose of this study, BeWo cell lines were used as substitutes for placental 
trophoblasts. As I have mentioned earlier, BeWo cell line originates from human 
choricarcinoma cells and when incubated with forskolin, it showed an increased level 
of intracellular cAMP in a time and dose dependent manner, which resulted in cells 
fusion and syncytia formation (multinucleated cell) which has the ability to secrete 
hCG hormone (Wice et al., 1990). 
In this study, several aspects of the role of mTOR on BeWo cells differentiation were 
investigated. First, I investigated the role of mTOR on forskolin-induced fusogenic 
gene expression. The results showed that, forskolin-treated BeWo cells showed 
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increased expression of fusogenic genes. In agreement with previous experiment 
which showed that stimulation of BeWo cells with forskolin resulted in either 
increased expression of fusogenic genes (Delidaki et al., 2011) or decreased 
expression of other genes such as mTOR and 4EBP genes. This suggested that 
forskolin changed the expression of various genes when it is used for BeWo cells 
differentiation (Mparmpakas et al., 2010). 
This experiment showed that mTOR might inhibit forskolin-induced fusogenic gene 
expression since the addition of rapmycin to forskolin-treated BeWo cells resulted in 
significant increase in expression of syncytin 1 and 2. 
The next part of this study was to investigate the effect of mTOR on forskolin-induced 
hCG secretion. hCG secretion by BeWo cells represents the biochemical marker of 
BeWo cells differentiation. The result showed that, rapamycin and AICAR have 
negative effect on forskolin-induced hCG secretion, which might indicate that mTOR 
is important for forskolin to induce hCG secretion by BeWo cells. However, 
compound C has no effect on forskolin-induced hCG secretion.  
In this study, by using the BeWo choriocarcinoma cell line and discerning pathway 
inhibitors, I have shown a dual action of mTOR on BeWo cell differentiation, a 
stimulatory effect on hCG secretion associated with inhibitory effect on fusogenic 
gene expression.  
Since compounds C and AICAR have been used in this experiment, it can be 
mentioned that I have also tested the effect of AMPK (mTOR signalling pathway 
inhibitor) on hCG secretion and fusogenic gene expression.  
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Furthermore, forskloin, through the activation of cAMP pathway, has been proven to 
increase level of 11-βHSD2 mRNA and activity in JEG-3 cells (Pasquarette et al., 
1996). In addition, in-vitro studies have proven that in cultured syncytiotrophoblast of 
term human placenta, the oxidase activity of 11βHSD is referred mainly to 11βHSD2 
(Sun et al., 1998).  
The results showed that mTOR exerts no effect on 11βHSD2 secretion by forskolin-
treated BeWo cells since neither compound C, nor does rapamycin affect 11βHSD2 
release by forskolin-stimulated BeWo cells. However, AICAR may have a direct 
inhibitory effect on forskolin-induced 11βHSD2 secretion.  
mTOR activity is controlled by many environmental signals, however, the exact 
mechanism of how different signals regulate mTOR remains vague. Among those 
signals is cAMP which was identified as one of the mTORC1 regulators. Researchers 
have noticed that the effect of forskolin-increased intracellular cAMP on 
Akt/mTOR/S6k1 pathway differs from one cell type to another. In  isolated rat islets, 
forskolin increased p70s6k phosphorylation in a dose dependent manner, and this 
effect was independent of insulin and was inhibited by rapamycin (Kwon et al., 2004).  
Another study demonstrated that in skeletal muscles, forskolin inhibited the 
stimulatory effect of insulin on Akt/mTOR pathway (Richmond et al., 2009). In 
addition, various studies have revealed that cAMP has an inhibitory effect on Akt 
phosphorylation at Ser473, which is essential for Akt protein kinase activity. cAMP 
also prevents the translocation of PDK1 to the plasma membrane which further inhibit 
Akt activity (Fang et al., 2000, Kim et al., 2001, Li et al., 2000). One study have shown 
a different mechanism through which cAMP inhibits mTORC1 activity where 
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elevated cAMP resulted in disassembly of both mTORC1 and mTORC2 (Xie et al., 
2011). 
I have shown that treatment of BeWo cells with forskolin almost eliminates mTOR 
phosphorylation at Ser2448 and Ser2481. Furthermore, the expression of T.mTOR 
was also inhibited and this might suggest that inhibition of mTOR signalling pathway 
is crucial for BeWo cells differentiation. Researchers have reported that the 
syncytialisation of BeWo cells results in down regulation of mTOR mRNA expression 
and its downstream signalling (p70s6k) when compared to untreated cells. They have 
referred this to the cessation of BeWo cells proliferation and the start of differentiation 
event (Mparmpakas et al., 2010). Coop et al have investigated the effect of prolonged 
treatment with rapamycin on the phosphorylation of mTOR Ser2448 and mTOR 
Ser2481 in HEK293 and U205 cells. They found that phosphorylation of mTOR 2448 
in rapamycin treated cells was markedly reduced with either acute (1hr) or prolonged 
treatment (24hrs). In contrast, phosphorylation of 2481 was not changed after the first 
one hour of treatment while it was completely absent after prolonged treatment (24 
hrs.) (Copp et al., 2009). AICAR also inhibits mTOR phosphorylation at Ser2448 in 
acute lymphocytic leukaemia (ALL) cells (Leclerc et al., 2010).This might indicate 
that P.mTOR (Ser2448) is one of mTORC1 components and P.mTOR (Ser2481) is 
probably part of mTORC2 (Copp et al., 2009). 
In BeWo cells, the results revealed that Akt phosphorylation at Ser473 was also 
inhibited by forskolin and up-regulated in rapamycin treated cells. The crosstalk 
between Akt and mTOR complex can be explained by positioning mTOR both in the 
upstream (mTORC2) and downstream (mTORC1) of Akt, since mTORC2 stimulates 
Akt phosphorylation at Ser473, while phosphorylation of Akt at Thr308 activates 
mTORC1 (Vincent et al., 2011). This was further confirmed by the fact that Akt 
121 
 
phosphorylation at Ser473 was selectively absent in mTORC2 lacking cells (Bhaskar 
and Hay, 2007).  
Up-regulation of Akt phosphorylation at Ser473 by rapamycin could be due to the 
inhibition of p70s6k activity (the downstream target of mTORC1) which exerts a 
negative feedback effect on mTORC2-stimulated Akt phosphorylation. The activation 
of Akt phosphorylation at Ser473 by rapamycin has weakened its antineoplastic effect. 
This was observed following the treatment of tumour cells with rapamycin (Sun et al., 
2005). This is a consequence of inhibition of negative feedback loop of IRS-1 on 
PI3K/AKT which is mTOR dependent, so by inhibiting mTOR, rapamycin also 
inhibits this feedback loop leading to activation of AKT (O'Reilly et al., 2006). This 
effect has also been demonstrated in rhabdomyosarcoma cell line where treatment of 
this tumour by rapamycin resulted in up-regulation of Akt phosphorylation at Ser473 
(Wan et al., 2006). 
One of important lower stream targets of mTOR is P.p70s6k (Thr389), an mTORC1 
substrate which is important for S6K1 activity. However, little is known regarding the 
regulation of p70s6K (Ser371) (Dann et al., 2007, Shin et al., 2011).  
In BeWo cells, forskolin inhibited P.p70s6k (Thr389) phosphorylation whereas it 
stimulated the phosphorylation at Ser371. P.p70s6k (Thr389) is the marker for 
mTORC1 activity, and this indicates that forskolin down regulates the upstream (Akt) 
and downstream (P.p70s6k Thr389) effectors of mTORC1. Some studies have shown 
that the regulation of Ser371 and Thr389 is different. For example, rapamycin 
completely inhibits Thr389 phosphorylation, while it only slightly inhibits Ser371 
phosphorylation (Varma and Khandelwal, 2007). Another difference is that Ser371 is 
not affected by serum starvation and insulin while Thr389 is considerably affected 
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(Shin et al., 2011). In addition, Tortin, an mTOR catalytic inhibitor and LY294002, a 
PI3-K/Akt pathway inhibitor have no effect on Ser371 phosphorylation, whereas both 
resulted in complete inhibition of Thr389 phosphorylation (Shin et al., 2011). Here we 
have shown for the first time that forskolin stimulates P.p70s6k phosphorylation at 
Ser371. 
I have also compared the expression of mTOR and its components in GDM placenta 
to normal placenta. In vitro studies have shown that hyperglycaemia results in 
inhibition of proliferation of first trimester model (BeWo, JEG3), hence, impaired 
function of placenta in first trimester due to hyperglycaemia can be expected  (Weiss 
et al., 2001).  
A large group of evidence demonstrated that in pregnancy complicated by diabetes, 
there is an association between increased foetal growth and increased expression and 
activity of placental glucose and amino acid transporters (Jansson et al., 2002). 
Nutrient transport across placenta is controlled by foetal, maternal and placental 
factors; among the placental factors is the mTOR which is considered to be a positive 
controller of amino acid transport (Roos et al., 2007). Furthermore, it has been reported 
that in a gestational diabetic mother, placental leucin transport is increased compared 
to large for gestational age. This was associated with an increase in the activity of 
system A amino acid transport in microvillous plasma membrane (MVM) of placenta 
from diabetic mother (Jansson et al., 2002). 
In-vitro researches have shown that the upstream regulators of mTOR such as leptin, 
insulin and IGF-I stimulate placental amino acid transport (Jansson et al., 2003) and 
mTOR positively regulates amino acid transport across placenta. This might indicate 
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that mTOR plays an important role in gestational diabetes, and abnormality in mTOR 
activity might be one of the causative factors for GDM pathology. 
Western mmunoblotting showed increased expression of total and phospho-mTOR 
and its downstream effectors (P.p70s6k Thr389) in placentas from pregnancy 
complicated with GDM compared with normal placentas. Furthermore, 
immunohistochemistry revealed increased total and phospho-mTOR staining in 
placentas from GDM compared to normal placentas. This indicates that, mTOR might 
play a role in pathophysiology of GDM. 
Surprisingly, there was no difference in the expression of P.Akt (Thr308) between 
GDM placentas and the control. This might indicate that the mTOR pathway in GDM 
due to P.Akt (Ser473) activation. mTORC2 expression is also increased in GDM 
placentas as demonstrated by increased expression of P.mTOR 2481 and increased 
phosphorylation of Akt (Ser473). 
GDM placenta also showed increased expression of 11βHSD2 compared to normal. 
Numerous studies have tested the effect of various protein on the expression of 
11βHSD2 in placenta and BeWo cells. One study has reported that epinephrine and 
nor-epinephrine down regulate placental 11βHSD2 gene expression in a manner faster 
than forskoin induced 11βHSD2 expression (Sarkar et al., 2001). Placental 11βHSD2 
expression is also inhibited by steroid (estrogen, progesterone) (Sun et al., 1998). On 
the other hand, retinoic acid (Tremblay et al., 1999), forskolin (Pasquarette et al., 
1996) and cAMP (Sun et al., 1998) up-regulate 11β HSD2 protein expression. 
In pregnancy complicated by IUGR, it has been reported that the gene expression of 
11-βHSD2 is significantly reduced compared with normal pregnancy which might 
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indicate that 11-βHSD2 is a major regulator of foetal growth during human pregnancy 
(McTernan et al., 2001). 
Our finding is in agreement with another study conducted by (Ma et al., 2012) in which 
they reported that the expression of 11βHSD2 was up-regulated at both mRNA and 
protein level in placenta of patients with GDM compared to normal placenta. 
Various studies have shown the role of protein O-GlcNAcylation in glucose induced 
insulin resistance (McClain et al., 2002, Vosseller et al., 2002). However, the 
relationship between O-GlcNac and PI3K/Akt/mTOR pathway is contradicting. Some 
studies have shown that increased activity and expression of OGT protein and O-
GlcNac acylation in muscle, liver cells and fat cells resulted in inhibition of insulin 
signalling, whereas other studies showed that O-GlcNac acylation does not induce 
insulin resistance (Krzeslak et al., 2014).  
Here, I have shown increased expression of OGT and O-GlcNac protein in GDM 
placenta compared to normal placenta and also in BeWo cells compared to normal 
placenta. The results have also shown decreased expression of both proteins in 
rapamycin treated BeWo cells compared to untreated cells. This might indicate the 
association between mTOR signalling pathway and O-GlcNAcylation which needs to 
be further investigated.  
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Conclusion 
In conclusion, I have shown that inhibition of mTOR by rapamycin reduced forskolin-
induced hCG release, whereas syncytin-1 and -2 mRNA expression was substantially 
augmented. I have also demonstrated that within 10min of forskolin treatment, there 
was a substantial reduction in basal mTOR phosphorylation at Ser2481 and Ser2448, 
which is required for mTOR activity. Additionally, increased expression of total and 
phospho-mTOR (Ser2448/2481) staining in GDM placenta. All these results suggest 
novel, distinct roles for mTOR in the control of trophoblast differentiation and may 
provide an explanation for the mechanisms of increased placental and fetal size in 
GDM.   
Further experiments investigating the effect of mTOR in a time and dose dependent 
manner are required to support my results and to further investigate the role of mTOR 
on BeWo cells differentiation. Future work should also include studying the effect of 
mTOR on hCG and steroid hormone secretion from placental explant of normal and 
GDM placentas to further strengthen my experimental finding on BeWo cells. Future 
experiments should also include a mass spectrometry to identify if mTOR is among 
the proteins which are involved in O.Glc-Nac modification.  
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